# PeptideScanner evidence objects: Tesamorelin

Every published version of the records placed with Tesamorelin, one section per evidence object. The section anchor is the object's path id; the JSON twin is https://peptidescanner.com/evidence/v1/peptides/tesamorelin.json. Selected public evidence only; not medical advice.

- Objects: 47
- Manifest: https://peptidescanner.com/evidence/v1/manifest.json

---

<a id="clinicaltrials-gov-nct00608023-tesamorelin-v1"></a>

## ClinicalTrials.gov record NCT00608023

> PeptideScanner retained ClinicalTrials.gov record NCT00608023 at 2026-07-30T19:35:26.307Z. Its registry update date was 2022-09-30, and PeptideScanner's reviewed identity mapping was tesamorelin.

- Evidence object: `story:clinicaltrials-gov-nct00608023-tesamorelin:v1`
- Evidence domain: Clinical trials
- Date in source: 2022-09-30
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00608023-tesamorelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tesamorelin.json#clinicaltrials-gov-nct00608023-tesamorelin-v1
- Content SHA-256: `a632559240cb603b42fe74de661c08dcc9c91bba42a34688583ef0d0bf184694`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00608023 ([`ctg-observation-nct00608023-2022-09-30-87ed20b33e66`](#source-ctg-observation-nct00608023-2022-09-30-87ed20b33e66))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00608023 at 2026-07-30T19:35:26.307Z. Its registry update date was 2022-09-30, and PeptideScanner's reviewed identity mapping was tesamorelin. ([`ctg-observation-nct00608023-2022-09-30-87ed20b33e66`](#source-ctg-observation-nct00608023-2022-09-30-87ed20b33e66))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00608023 at 2026-07-30T19:35:26.307Z. Its registry update date was 2022-09-30, and PeptideScanner's reviewed identity mapping was tesamorelin. ([`ctg-observation-nct00608023-2022-09-30-87ed20b33e66`](#source-ctg-observation-nct00608023-2022-09-30-87ed20b33e66))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00608023-2022-09-30-87ed20b33e66`](#source-ctg-observation-nct00608023-2022-09-30-87ed20b33e66))

### Sources

<a id="source-ctg-observation-nct00608023-2022-09-30-87ed20b33e66"></a>
- **ClinicalTrials.gov record NCT00608023 · retained source version 2022-09-30:87ed20b33e66aadf1d77985e5901e20f0c57f8ddf6727384f4c070dea2968a2f** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00608023) (`ctg-observation-nct00608023-2022-09-30-87ed20b33e66`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00608023." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/tesamorelin.json#clinicaltrials-gov-nct00608023-tesamorelin-v1 SHA-256: a632559240cb603b42fe74de661c08dcc9c91bba42a34688583ef0d0bf184694.

---

<a id="clinicaltrials-gov-nct00850564-tesamorelin-v1"></a>

## ClinicalTrials.gov record NCT00850564

> PeptideScanner retained ClinicalTrials.gov record NCT00850564 at 2026-07-30T22:15:58.888Z. Its registry update date was 2011-04-19, and PeptideScanner's reviewed identity mapping was tesamorelin.

- Evidence object: `story:clinicaltrials-gov-nct00850564-tesamorelin:v1`
- Evidence domain: Clinical trials
- Date in source: 2011-04-19
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00850564-tesamorelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tesamorelin.json#clinicaltrials-gov-nct00850564-tesamorelin-v1
- Content SHA-256: `a3980728eb88493f3c5744bf0c4cb348ab3a45a7e7a063627499cde0a4362610`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00850564 ([`ctg-observation-nct00850564-2011-04-19-e3aa6ea0d4cb`](#source-ctg-observation-nct00850564-2011-04-19-e3aa6ea0d4cb))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00850564 at 2026-07-30T22:15:58.888Z. Its registry update date was 2011-04-19, and PeptideScanner's reviewed identity mapping was tesamorelin. ([`ctg-observation-nct00850564-2011-04-19-e3aa6ea0d4cb`](#source-ctg-observation-nct00850564-2011-04-19-e3aa6ea0d4cb))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00850564 at 2026-07-30T22:15:58.888Z. Its registry update date was 2011-04-19, and PeptideScanner's reviewed identity mapping was tesamorelin. ([`ctg-observation-nct00850564-2011-04-19-e3aa6ea0d4cb`](#source-ctg-observation-nct00850564-2011-04-19-e3aa6ea0d4cb))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00850564-2011-04-19-e3aa6ea0d4cb`](#source-ctg-observation-nct00850564-2011-04-19-e3aa6ea0d4cb))

### Sources

<a id="source-ctg-observation-nct00850564-2011-04-19-e3aa6ea0d4cb"></a>
- **ClinicalTrials.gov record NCT00850564 · retained source version 2011-04-19:e3aa6ea0d4cb981f8d75248c12a439628f210cfab2273ed2e97f769d6efe9ad5** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00850564) (`ctg-observation-nct00850564-2011-04-19-e3aa6ea0d4cb`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00850564." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/tesamorelin.json#clinicaltrials-gov-nct00850564-tesamorelin-v1 SHA-256: a3980728eb88493f3c5744bf0c4cb348ab3a45a7e7a063627499cde0a4362610.

---

<a id="clinicaltrials-gov-nct01263717-tesamorelin-v1"></a>

## ClinicalTrials.gov record NCT01263717

> PeptideScanner retained ClinicalTrials.gov record NCT01263717 at 2026-07-30T21:22:00.255Z. Its registry update date was 2017-10-30, and PeptideScanner's reviewed identity mapping was tesamorelin.

- Evidence object: `story:clinicaltrials-gov-nct01263717-tesamorelin:v1`
- Evidence domain: Clinical trials
- Date in source: 2017-10-30
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01263717-tesamorelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tesamorelin.json#clinicaltrials-gov-nct01263717-tesamorelin-v1
- Content SHA-256: `2727b3674f41913940d8ed388bb2e20450dff409aeb8a7e86c3c8eb81ea32206`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01263717 ([`ctg-observation-nct01263717-2017-10-30-6738333a7c13`](#source-ctg-observation-nct01263717-2017-10-30-6738333a7c13))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01263717 at 2026-07-30T21:22:00.255Z. Its registry update date was 2017-10-30, and PeptideScanner's reviewed identity mapping was tesamorelin. ([`ctg-observation-nct01263717-2017-10-30-6738333a7c13`](#source-ctg-observation-nct01263717-2017-10-30-6738333a7c13))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01263717 at 2026-07-30T21:22:00.255Z. Its registry update date was 2017-10-30, and PeptideScanner's reviewed identity mapping was tesamorelin. ([`ctg-observation-nct01263717-2017-10-30-6738333a7c13`](#source-ctg-observation-nct01263717-2017-10-30-6738333a7c13))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01263717-2017-10-30-6738333a7c13`](#source-ctg-observation-nct01263717-2017-10-30-6738333a7c13))

### Sources

<a id="source-ctg-observation-nct01263717-2017-10-30-6738333a7c13"></a>
- **ClinicalTrials.gov record NCT01263717 · retained source version 2017-10-30:6738333a7c130040e9d7e582dfa3b10b4fe72e2945cb8af1be8cf3e545162279** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01263717) (`ctg-observation-nct01263717-2017-10-30-6738333a7c13`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01263717." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/tesamorelin.json#clinicaltrials-gov-nct01263717-tesamorelin-v1 SHA-256: 2727b3674f41913940d8ed388bb2e20450dff409aeb8a7e86c3c8eb81ea32206.

---

<a id="clinicaltrials-gov-nct02012556-tesamorelin-v1"></a>

## ClinicalTrials.gov record NCT02012556

> PeptideScanner retained ClinicalTrials.gov record NCT02012556 at 2026-07-30T21:55:56.632Z. Its registry update date was 2013-12-16, and PeptideScanner's reviewed identity mapping was tesamorelin.

- Evidence object: `story:clinicaltrials-gov-nct02012556-tesamorelin:v1`
- Evidence domain: Clinical trials
- Date in source: 2013-12-16
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-09-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02012556-tesamorelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tesamorelin.json#clinicaltrials-gov-nct02012556-tesamorelin-v1
- Content SHA-256: `808a43329a5a4877872200cad210f80f7b20c40dcbc558ad2dc9568d210001d0`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02012556 ([`ctg-observation-nct02012556-2013-12-16-3db960ff254d`](#source-ctg-observation-nct02012556-2013-12-16-3db960ff254d))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02012556 at 2026-07-30T21:55:56.632Z. Its registry update date was 2013-12-16, and PeptideScanner's reviewed identity mapping was tesamorelin. ([`ctg-observation-nct02012556-2013-12-16-3db960ff254d`](#source-ctg-observation-nct02012556-2013-12-16-3db960ff254d))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02012556 at 2026-07-30T21:55:56.632Z. Its registry update date was 2013-12-16, and PeptideScanner's reviewed identity mapping was tesamorelin. ([`ctg-observation-nct02012556-2013-12-16-3db960ff254d`](#source-ctg-observation-nct02012556-2013-12-16-3db960ff254d))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02012556-2013-12-16-3db960ff254d`](#source-ctg-observation-nct02012556-2013-12-16-3db960ff254d))

### Sources

<a id="source-ctg-observation-nct02012556-2013-12-16-3db960ff254d"></a>
- **ClinicalTrials.gov record NCT02012556 · retained source version 2013-12-16:3db960ff254d78667f3acc7acd7868e7a8afd7e8d0ad6e6314342a203ed75c58** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02012556) (`ctg-observation-nct02012556-2013-12-16-3db960ff254d`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02012556." Version 1, published 2026-09-09. https://peptidescanner.com/evidence/v1/peptides/tesamorelin.json#clinicaltrials-gov-nct02012556-tesamorelin-v1 SHA-256: 808a43329a5a4877872200cad210f80f7b20c40dcbc558ad2dc9568d210001d0.

---

<a id="clinicaltrials-gov-nct02196831-tesamorelin-v1"></a>

## ClinicalTrials.gov record NCT02196831

> PeptideScanner retained ClinicalTrials.gov record NCT02196831 at 2026-07-30T20:33:20.623Z. Its registry update date was 2020-01-27, and PeptideScanner's reviewed identity mapping was tesamorelin.

- Evidence object: `story:clinicaltrials-gov-nct02196831-tesamorelin:v1`
- Evidence domain: Clinical trials
- Date in source: 2020-01-27
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02196831-tesamorelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tesamorelin.json#clinicaltrials-gov-nct02196831-tesamorelin-v1
- Content SHA-256: `7816099f4da57fc3ab44dcfcceb9134f535f14bcf246dcbe41e9b8f247cdc44e`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02196831 ([`ctg-observation-nct02196831-2020-01-27-6949b106f4e5`](#source-ctg-observation-nct02196831-2020-01-27-6949b106f4e5))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02196831 at 2026-07-30T20:33:20.623Z. Its registry update date was 2020-01-27, and PeptideScanner's reviewed identity mapping was tesamorelin. ([`ctg-observation-nct02196831-2020-01-27-6949b106f4e5`](#source-ctg-observation-nct02196831-2020-01-27-6949b106f4e5))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02196831 at 2026-07-30T20:33:20.623Z. Its registry update date was 2020-01-27, and PeptideScanner's reviewed identity mapping was tesamorelin. ([`ctg-observation-nct02196831-2020-01-27-6949b106f4e5`](#source-ctg-observation-nct02196831-2020-01-27-6949b106f4e5))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02196831-2020-01-27-6949b106f4e5`](#source-ctg-observation-nct02196831-2020-01-27-6949b106f4e5))

### Sources

<a id="source-ctg-observation-nct02196831-2020-01-27-6949b106f4e5"></a>
- **ClinicalTrials.gov record NCT02196831 · retained source version 2020-01-27:6949b106f4e5a702e91a9ee7a8429948daad461514ce2523818c431f2e2e04c4** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02196831) (`ctg-observation-nct02196831-2020-01-27-6949b106f4e5`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02196831." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/tesamorelin.json#clinicaltrials-gov-nct02196831-tesamorelin-v1 SHA-256: 7816099f4da57fc3ab44dcfcceb9134f535f14bcf246dcbe41e9b8f247cdc44e.

---

<a id="clinicaltrials-gov-nct02553603-tesamorelin-v1"></a>

## ClinicalTrials.gov record NCT02553603

> PeptideScanner retained ClinicalTrials.gov record NCT02553603 at 2026-07-30T20:43:27.316Z. Its registry update date was 2019-11-04, and PeptideScanner's reviewed identity mapping was tesamorelin.

- Evidence object: `story:clinicaltrials-gov-nct02553603-tesamorelin:v1`
- Evidence domain: Clinical trials
- Date in source: 2019-11-04
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02553603-tesamorelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tesamorelin.json#clinicaltrials-gov-nct02553603-tesamorelin-v1
- Content SHA-256: `a5e8c5e24640c9d6ad1a114f1fe0a47064607f84a92eff9b1f0e4ed469dde152`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02553603 ([`ctg-observation-nct02553603-2019-11-04-5440d24f04c7`](#source-ctg-observation-nct02553603-2019-11-04-5440d24f04c7))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02553603 at 2026-07-30T20:43:27.316Z. Its registry update date was 2019-11-04, and PeptideScanner's reviewed identity mapping was tesamorelin. ([`ctg-observation-nct02553603-2019-11-04-5440d24f04c7`](#source-ctg-observation-nct02553603-2019-11-04-5440d24f04c7))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02553603 at 2026-07-30T20:43:27.316Z. Its registry update date was 2019-11-04, and PeptideScanner's reviewed identity mapping was tesamorelin. ([`ctg-observation-nct02553603-2019-11-04-5440d24f04c7`](#source-ctg-observation-nct02553603-2019-11-04-5440d24f04c7))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02553603-2019-11-04-5440d24f04c7`](#source-ctg-observation-nct02553603-2019-11-04-5440d24f04c7))

### Sources

<a id="source-ctg-observation-nct02553603-2019-11-04-5440d24f04c7"></a>
- **ClinicalTrials.gov record NCT02553603 · retained source version 2019-11-04:5440d24f04c76f23b264240c5404a13d24e6c034852e4d1a165b6473665b22cd** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02553603) (`ctg-observation-nct02553603-2019-11-04-5440d24f04c7`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02553603." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/tesamorelin.json#clinicaltrials-gov-nct02553603-tesamorelin-v1 SHA-256: a5e8c5e24640c9d6ad1a114f1fe0a47064607f84a92eff9b1f0e4ed469dde152.

---

<a id="clinicaltrials-gov-nct02572323-tesamorelin-v1"></a>

## ClinicalTrials.gov record NCT02572323

> PeptideScanner retained ClinicalTrials.gov record NCT02572323 at 2026-07-30T16:22:22.328Z. Its registry update date was 2026-03-12, and PeptideScanner's reviewed identity mapping was tesamorelin.

- Evidence object: `story:clinicaltrials-gov-nct02572323-tesamorelin:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-03-12
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02572323-tesamorelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tesamorelin.json#clinicaltrials-gov-nct02572323-tesamorelin-v1
- Content SHA-256: `77721312ffd4bddb727b44aec02dc8daa19a57dfbc34980c13457109d90293ac`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02572323 ([`ctg-observation-nct02572323-2026-03-12-d7d7392d6688`](#source-ctg-observation-nct02572323-2026-03-12-d7d7392d6688))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02572323 at 2026-07-30T16:22:22.328Z. Its registry update date was 2026-03-12, and PeptideScanner's reviewed identity mapping was tesamorelin. ([`ctg-observation-nct02572323-2026-03-12-d7d7392d6688`](#source-ctg-observation-nct02572323-2026-03-12-d7d7392d6688))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02572323 at 2026-07-30T16:22:22.328Z. Its registry update date was 2026-03-12, and PeptideScanner's reviewed identity mapping was tesamorelin. ([`ctg-observation-nct02572323-2026-03-12-d7d7392d6688`](#source-ctg-observation-nct02572323-2026-03-12-d7d7392d6688))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02572323-2026-03-12-d7d7392d6688`](#source-ctg-observation-nct02572323-2026-03-12-d7d7392d6688))

### Sources

<a id="source-ctg-observation-nct02572323-2026-03-12-d7d7392d6688"></a>
- **ClinicalTrials.gov record NCT02572323 · retained source version 2026-03-12:d7d7392d6688e4b6ab8add8cdb202339b63a846e03517c7b10a4debf1f4650df** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02572323) (`ctg-observation-nct02572323-2026-03-12-d7d7392d6688`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02572323." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/tesamorelin.json#clinicaltrials-gov-nct02572323-tesamorelin-v1 SHA-256: 77721312ffd4bddb727b44aec02dc8daa19a57dfbc34980c13457109d90293ac.

---

<a id="clinicaltrials-gov-nct03150511-tesamorelin-v1"></a>

## ClinicalTrials.gov record NCT03150511

> PeptideScanner retained ClinicalTrials.gov record NCT03150511 at 2026-07-30T18:19:48.216Z. Its registry update date was 2025-11-12, and PeptideScanner's reviewed identity mapping was tesamorelin.

- Evidence object: `story:clinicaltrials-gov-nct03150511-tesamorelin:v1`
- Evidence domain: Clinical trials
- Date in source: 2025-11-12
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03150511-tesamorelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tesamorelin.json#clinicaltrials-gov-nct03150511-tesamorelin-v1
- Content SHA-256: `b0aceaa369f3d318c7dab9948733eb1f1371dfa0c076f359a72c38857a0c0231`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03150511 ([`ctg-observation-nct03150511-2025-11-12-65e14fe63370`](#source-ctg-observation-nct03150511-2025-11-12-65e14fe63370))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03150511 at 2026-07-30T18:19:48.216Z. Its registry update date was 2025-11-12, and PeptideScanner's reviewed identity mapping was tesamorelin. ([`ctg-observation-nct03150511-2025-11-12-65e14fe63370`](#source-ctg-observation-nct03150511-2025-11-12-65e14fe63370))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03150511 at 2026-07-30T18:19:48.216Z. Its registry update date was 2025-11-12, and PeptideScanner's reviewed identity mapping was tesamorelin. ([`ctg-observation-nct03150511-2025-11-12-65e14fe63370`](#source-ctg-observation-nct03150511-2025-11-12-65e14fe63370))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03150511-2025-11-12-65e14fe63370`](#source-ctg-observation-nct03150511-2025-11-12-65e14fe63370))

### Sources

<a id="source-ctg-observation-nct03150511-2025-11-12-65e14fe63370"></a>
- **ClinicalTrials.gov record NCT03150511 · retained source version 2025-11-12:65e14fe63370442d236291e99756db31b915b02605c9401b8ed7a83955aa6804** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03150511) (`ctg-observation-nct03150511-2025-11-12-65e14fe63370`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03150511." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/tesamorelin.json#clinicaltrials-gov-nct03150511-tesamorelin-v1 SHA-256: b0aceaa369f3d318c7dab9948733eb1f1371dfa0c076f359a72c38857a0c0231.

---

<a id="clinicaltrials-gov-nct03150511-tesamorelin-v2"></a>

## ClinicalTrials.gov record NCT03150511

> PeptideScanner retained ClinicalTrials.gov record NCT03150511 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-09, and PeptideScanner's reviewed identity mapping was tesamorelin.

- Evidence object: `story:clinicaltrials-gov-nct03150511-tesamorelin:v2`
- Evidence domain: Clinical trials
- Date in source: 2026-11-09
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03150511-tesamorelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tesamorelin.json#clinicaltrials-gov-nct03150511-tesamorelin-v2
- Content SHA-256: `08a03193ffe199abf58efa6c4d9a55e88f07dbc30c8868a6823723437bfc1147`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03150511 ([`ctg-observation-nct03150511-2025-11-12-65e14fe63370-r2`](#source-ctg-observation-nct03150511-2025-11-12-65e14fe63370-r2))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03150511 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-09, and PeptideScanner's reviewed identity mapping was tesamorelin. ([`ctg-observation-nct03150511-2025-11-12-65e14fe63370-r2`](#source-ctg-observation-nct03150511-2025-11-12-65e14fe63370-r2))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03150511 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-09, and PeptideScanner's reviewed identity mapping was tesamorelin. ([`ctg-observation-nct03150511-2025-11-12-65e14fe63370-r2`](#source-ctg-observation-nct03150511-2025-11-12-65e14fe63370-r2))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03150511-2025-11-12-65e14fe63370-r2`](#source-ctg-observation-nct03150511-2025-11-12-65e14fe63370-r2))

### Sources

<a id="source-ctg-observation-nct03150511-2025-11-12-65e14fe63370-r2"></a>
- **ClinicalTrials.gov record NCT03150511 · retained source version 2026-11-09:9098411ceb32fcb7f450cbc2816eb0995a62ef02bd91f6c02e43d6e3c9b5ae59** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03150511) (`ctg-observation-nct03150511-2025-11-12-65e14fe63370-r2`)

### Correction lineage

updated on 2026-11-15: ClinicalTrials.gov posted a newer version of NCT03150511, with a registry update date of 2026-11-09. This version reports that observation; the earlier retained observation remains available as version 1.
- Supersedes version: 1
- Correction sources: [`ctg-observation-nct03150511-2025-11-12-65e14fe63370-r2`](#source-ctg-observation-nct03150511-2025-11-12-65e14fe63370-r2)

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03150511." Version 2, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/tesamorelin.json#clinicaltrials-gov-nct03150511-tesamorelin-v2 SHA-256: 08a03193ffe199abf58efa6c4d9a55e88f07dbc30c8868a6823723437bfc1147.

---

<a id="clinicaltrials-gov-nct03375788-tesamorelin-v1"></a>

## ClinicalTrials.gov record NCT03375788

> PeptideScanner retained ClinicalTrials.gov record NCT03375788 at 2026-07-30T18:19:48.220Z. Its registry update date was 2025-11-20, and PeptideScanner's reviewed identity mapping was tesamorelin.

- Evidence object: `story:clinicaltrials-gov-nct03375788-tesamorelin:v1`
- Evidence domain: Clinical trials
- Date in source: 2025-11-20
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03375788-tesamorelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tesamorelin.json#clinicaltrials-gov-nct03375788-tesamorelin-v1
- Content SHA-256: `372ee5abd33e3a1ecaff044e0eeb69d972518d2436a051b4eb49b16d32383d72`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03375788 ([`ctg-observation-nct03375788-2025-11-20-aa96619322ff`](#source-ctg-observation-nct03375788-2025-11-20-aa96619322ff))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03375788 at 2026-07-30T18:19:48.220Z. Its registry update date was 2025-11-20, and PeptideScanner's reviewed identity mapping was tesamorelin. ([`ctg-observation-nct03375788-2025-11-20-aa96619322ff`](#source-ctg-observation-nct03375788-2025-11-20-aa96619322ff))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03375788 at 2026-07-30T18:19:48.220Z. Its registry update date was 2025-11-20, and PeptideScanner's reviewed identity mapping was tesamorelin. ([`ctg-observation-nct03375788-2025-11-20-aa96619322ff`](#source-ctg-observation-nct03375788-2025-11-20-aa96619322ff))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03375788-2025-11-20-aa96619322ff`](#source-ctg-observation-nct03375788-2025-11-20-aa96619322ff))

### Sources

<a id="source-ctg-observation-nct03375788-2025-11-20-aa96619322ff"></a>
- **ClinicalTrials.gov record NCT03375788 · retained source version 2025-11-20:aa96619322ff0d7687a6cd01828c586bb60154fbae05f5439bc5adf6f365af92** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03375788) (`ctg-observation-nct03375788-2025-11-20-aa96619322ff`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03375788." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/tesamorelin.json#clinicaltrials-gov-nct03375788-tesamorelin-v1 SHA-256: 372ee5abd33e3a1ecaff044e0eeb69d972518d2436a051b4eb49b16d32383d72.

---

<a id="clinicaltrials-gov-nct06554717-tesamorelin-v1"></a>

## ClinicalTrials.gov record NCT06554717

> PeptideScanner retained ClinicalTrials.gov record NCT06554717 at 2026-07-30T16:19:36.918Z. Its registry update date was 2026-05-19, and PeptideScanner's reviewed identity mapping was tesamorelin.

- Evidence object: `story:clinicaltrials-gov-nct06554717-tesamorelin:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-05-19
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-08
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06554717-tesamorelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tesamorelin.json#clinicaltrials-gov-nct06554717-tesamorelin-v1
- Content SHA-256: `757bff63eacee51e67ed584bf6c5145bd5ae6a8a25800d5e2d826475fe165528`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06554717 ([`ctg-observation-nct06554717-2026-05-19-778551eac8ae`](#source-ctg-observation-nct06554717-2026-05-19-778551eac8ae))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06554717 at 2026-07-30T16:19:36.918Z. Its registry update date was 2026-05-19, and PeptideScanner's reviewed identity mapping was tesamorelin. ([`ctg-observation-nct06554717-2026-05-19-778551eac8ae`](#source-ctg-observation-nct06554717-2026-05-19-778551eac8ae))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06554717 at 2026-07-30T16:19:36.918Z. Its registry update date was 2026-05-19, and PeptideScanner's reviewed identity mapping was tesamorelin. ([`ctg-observation-nct06554717-2026-05-19-778551eac8ae`](#source-ctg-observation-nct06554717-2026-05-19-778551eac8ae))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06554717-2026-05-19-778551eac8ae`](#source-ctg-observation-nct06554717-2026-05-19-778551eac8ae))

### Sources

<a id="source-ctg-observation-nct06554717-2026-05-19-778551eac8ae"></a>
- **ClinicalTrials.gov record NCT06554717 · retained source version 2026-05-19:778551eac8ae5487f8e1cbd2d1ffa5adb07326643d805b8f6a7f79c90b905b2a** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06554717) (`ctg-observation-nct06554717-2026-05-19-778551eac8ae`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06554717." Version 1, published 2026-08-08. https://peptidescanner.com/evidence/v1/peptides/tesamorelin.json#clinicaltrials-gov-nct06554717-tesamorelin-v1 SHA-256: 757bff63eacee51e67ed584bf6c5145bd5ae6a8a25800d5e2d826475fe165528.

---

<a id="clinicaltrials-gov-nct07481734-tesamorelin-v1"></a>

## ClinicalTrials.gov record NCT07481734

> PeptideScanner retained ClinicalTrials.gov record NCT07481734 at 2026-07-30T16:22:22.324Z. Its registry update date was 2026-03-19, and PeptideScanner's reviewed identity mapping was tesamorelin.

- Evidence object: `story:clinicaltrials-gov-nct07481734-tesamorelin:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-03-19
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-08
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07481734-tesamorelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tesamorelin.json#clinicaltrials-gov-nct07481734-tesamorelin-v1
- Content SHA-256: `5d0d8a72faa37afbe554300fbd1c03fb586d395102559d309512f88e9c9da357`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07481734 ([`ctg-observation-nct07481734-2026-03-19-79e26d9bce31`](#source-ctg-observation-nct07481734-2026-03-19-79e26d9bce31))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07481734 at 2026-07-30T16:22:22.324Z. Its registry update date was 2026-03-19, and PeptideScanner's reviewed identity mapping was tesamorelin. ([`ctg-observation-nct07481734-2026-03-19-79e26d9bce31`](#source-ctg-observation-nct07481734-2026-03-19-79e26d9bce31))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07481734 at 2026-07-30T16:22:22.324Z. Its registry update date was 2026-03-19, and PeptideScanner's reviewed identity mapping was tesamorelin. ([`ctg-observation-nct07481734-2026-03-19-79e26d9bce31`](#source-ctg-observation-nct07481734-2026-03-19-79e26d9bce31))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07481734-2026-03-19-79e26d9bce31`](#source-ctg-observation-nct07481734-2026-03-19-79e26d9bce31))

### Sources

<a id="source-ctg-observation-nct07481734-2026-03-19-79e26d9bce31"></a>
- **ClinicalTrials.gov record NCT07481734 · retained source version 2026-03-19:79e26d9bce317d5509d2c5e266b142d6817cbc5b738f52bccb7f92f89d1db2be** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07481734) (`ctg-observation-nct07481734-2026-03-19-79e26d9bce31`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07481734." Version 1, published 2026-08-08. https://peptidescanner.com/evidence/v1/peptides/tesamorelin.json#clinicaltrials-gov-nct07481734-tesamorelin-v1 SHA-256: 5d0d8a72faa37afbe554300fbd1c03fb586d395102559d309512f88e9c9da357.

---

<a id="clinicaltrials-gov-nct07481734-tesamorelin-v2"></a>

## ClinicalTrials.gov record NCT07481734

> PeptideScanner retained ClinicalTrials.gov record NCT07481734 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was tesamorelin.

- Evidence object: `story:clinicaltrials-gov-nct07481734-tesamorelin:v2`
- Evidence domain: Clinical trials
- Date in source: 2026-11-12
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07481734-tesamorelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tesamorelin.json#clinicaltrials-gov-nct07481734-tesamorelin-v2
- Content SHA-256: `e9d5c8af869ee20c2b8b223098aea735a8efd480df3f55186912c240a72a511e`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07481734 ([`ctg-observation-nct07481734-2026-03-19-79e26d9bce31-r2`](#source-ctg-observation-nct07481734-2026-03-19-79e26d9bce31-r2))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07481734 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was tesamorelin. ([`ctg-observation-nct07481734-2026-03-19-79e26d9bce31-r2`](#source-ctg-observation-nct07481734-2026-03-19-79e26d9bce31-r2))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07481734 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was tesamorelin. ([`ctg-observation-nct07481734-2026-03-19-79e26d9bce31-r2`](#source-ctg-observation-nct07481734-2026-03-19-79e26d9bce31-r2))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07481734-2026-03-19-79e26d9bce31-r2`](#source-ctg-observation-nct07481734-2026-03-19-79e26d9bce31-r2))

### Sources

<a id="source-ctg-observation-nct07481734-2026-03-19-79e26d9bce31-r2"></a>
- **ClinicalTrials.gov record NCT07481734 · retained source version 2026-11-12:944f22a8653ce80e071c725e8e3cce5485f2a68ffd25ad5ecc2e9db3e763fea4** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07481734) (`ctg-observation-nct07481734-2026-03-19-79e26d9bce31-r2`)

### Correction lineage

updated on 2026-11-15: ClinicalTrials.gov posted a newer version of NCT07481734, with a registry update date of 2026-11-12. This version reports that observation; the earlier retained observation remains available as version 1.
- Supersedes version: 1
- Correction sources: [`ctg-observation-nct07481734-2026-03-19-79e26d9bce31-r2`](#source-ctg-observation-nct07481734-2026-03-19-79e26d9bce31-r2)

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07481734." Version 2, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/tesamorelin.json#clinicaltrials-gov-nct07481734-tesamorelin-v2 SHA-256: e9d5c8af869ee20c2b8b223098aea735a8efd480df3f55186912c240a72a511e.

---

<a id="dailymed-label-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v1-v1"></a>

## Tesamorelin DailyMed SPL version 1

> DailyMed lists Structured Product Labeling version 1 for the reviewed Tesamorelin label family with a published date of 2019-11-05. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

- Evidence object: `story:dailymed-label-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v1:v1`
- Evidence domain: Regulatory
- Date in source: 2019-11-05
- Source checked: 2026-08-22
- Published by PeptideScanner: 2026-08-22
- Story landing page: https://peptidescanner.com/stories/dailymed-label-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v1/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tesamorelin.json#dailymed-label-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v1-v1
- Content SHA-256: `5be33b44dfac2cdcaa03f487fa498c38d4ed945fe80c3e65c249d0681b308585`

### Claims and source pins

#### Headline

Tesamorelin DailyMed SPL version 1 ([`dailymed-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v1-history`](#source-dailymed-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v1-history))

#### Summary

DailyMed lists Structured Product Labeling version 1 for the reviewed Tesamorelin label family with a published date of 2019-11-05. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v1-history`](#source-dailymed-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v1-history))

#### Paragraph 1

DailyMed lists Structured Product Labeling version 1 for the reviewed Tesamorelin label family with a published date of 2019-11-05. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v1-history`](#source-dailymed-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v1-history))

#### Paragraph 2

This page reports that DailyMed lists an available Structured Product Labeling version for the reviewed label family and links the exact historical ZIP. It does not reproduce label text, identify which sections changed, establish FDA approval, interpret safety or effectiveness, or provide medical guidance. ([`dailymed-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v1-history`](#source-dailymed-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v1-history))

### Sources

<a id="source-dailymed-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v1-history"></a>
- **DailyMed SPL SET ID 3d783378-b02d-4f19-99dd-0fc91a042224 · SPL version 1 · published 2019-11-05 · retained ZIP SHA-256 9af36e5bb55ce8f3358d866d44b5cdce07a6d73716b5ff481dc2cd5464aa4eb5** — DailyMed · U.S. National Library of Medicine; class A. [Open source](https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=3d783378-b02d-4f19-99dd-0fc91a042224&version=1) (`dailymed-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v1-history`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Tesamorelin DailyMed SPL version 1." Version 1, published 2026-08-22. https://peptidescanner.com/evidence/v1/peptides/tesamorelin.json#dailymed-label-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v1-v1 SHA-256: 5be33b44dfac2cdcaa03f487fa498c38d4ed945fe80c3e65c249d0681b308585.

---

<a id="dailymed-label-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v2-v1"></a>

## Tesamorelin DailyMed SPL version 2

> DailyMed lists Structured Product Labeling version 2 for the reviewed Tesamorelin label family with a published date of 2020-04-22. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

- Evidence object: `story:dailymed-label-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v2:v1`
- Evidence domain: Regulatory
- Date in source: 2020-04-22
- Source checked: 2026-08-22
- Published by PeptideScanner: 2026-08-22
- Story landing page: https://peptidescanner.com/stories/dailymed-label-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v2/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tesamorelin.json#dailymed-label-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v2-v1
- Content SHA-256: `18a4f13be6f4b8d87fa97a7807675a1432ec1fe844bec9203d6a65ffdad4ca8e`

### Claims and source pins

#### Headline

Tesamorelin DailyMed SPL version 2 ([`dailymed-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v2-history`](#source-dailymed-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v2-history))

#### Summary

DailyMed lists Structured Product Labeling version 2 for the reviewed Tesamorelin label family with a published date of 2020-04-22. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v2-history`](#source-dailymed-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v2-history))

#### Paragraph 1

DailyMed lists Structured Product Labeling version 2 for the reviewed Tesamorelin label family with a published date of 2020-04-22. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v2-history`](#source-dailymed-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v2-history))

#### Paragraph 2

This page reports that DailyMed lists an available Structured Product Labeling version for the reviewed label family and links the exact historical ZIP. It does not reproduce label text, identify which sections changed, establish FDA approval, interpret safety or effectiveness, or provide medical guidance. ([`dailymed-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v2-history`](#source-dailymed-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v2-history))

### Sources

<a id="source-dailymed-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v2-history"></a>
- **DailyMed SPL SET ID 3d783378-b02d-4f19-99dd-0fc91a042224 · SPL version 2 · published 2020-04-22 · retained ZIP SHA-256 20fd3e574d333ee112a838c604fea4ea1c9c6837ecb4465998a2b2ad5119c53d** — DailyMed · U.S. National Library of Medicine; class A. [Open source](https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=3d783378-b02d-4f19-99dd-0fc91a042224&version=2) (`dailymed-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v2-history`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Tesamorelin DailyMed SPL version 2." Version 1, published 2026-08-22. https://peptidescanner.com/evidence/v1/peptides/tesamorelin.json#dailymed-label-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v2-v1 SHA-256: 18a4f13be6f4b8d87fa97a7807675a1432ec1fe844bec9203d6a65ffdad4ca8e.

---

<a id="dailymed-label-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v3-v1"></a>

## Tesamorelin DailyMed SPL version 3

> DailyMed lists Structured Product Labeling version 3 for the reviewed Tesamorelin label family with a published date of 2021-12-03. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

- Evidence object: `story:dailymed-label-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v3:v1`
- Evidence domain: Regulatory
- Date in source: 2021-12-03
- Source checked: 2026-08-22
- Published by PeptideScanner: 2026-08-22
- Story landing page: https://peptidescanner.com/stories/dailymed-label-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v3/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tesamorelin.json#dailymed-label-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v3-v1
- Content SHA-256: `0cc39399e8f8253c4eec414573d930731437c4a535293ca90a1ea6f072d4c4d6`

### Claims and source pins

#### Headline

Tesamorelin DailyMed SPL version 3 ([`dailymed-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v3-history`](#source-dailymed-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v3-history))

#### Summary

DailyMed lists Structured Product Labeling version 3 for the reviewed Tesamorelin label family with a published date of 2021-12-03. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v3-history`](#source-dailymed-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v3-history))

#### Paragraph 1

DailyMed lists Structured Product Labeling version 3 for the reviewed Tesamorelin label family with a published date of 2021-12-03. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v3-history`](#source-dailymed-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v3-history))

#### Paragraph 2

This page reports that DailyMed lists an available Structured Product Labeling version for the reviewed label family and links the exact historical ZIP. It does not reproduce label text, identify which sections changed, establish FDA approval, interpret safety or effectiveness, or provide medical guidance. ([`dailymed-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v3-history`](#source-dailymed-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v3-history))

### Sources

<a id="source-dailymed-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v3-history"></a>
- **DailyMed SPL SET ID 3d783378-b02d-4f19-99dd-0fc91a042224 · SPL version 3 · published 2021-12-03 · retained ZIP SHA-256 870dec508ec2a383905b5243f14a6f8f58b7c601acb3f4f0916ede7c48c2e454** — DailyMed · U.S. National Library of Medicine; class A. [Open source](https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=3d783378-b02d-4f19-99dd-0fc91a042224&version=3) (`dailymed-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v3-history`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Tesamorelin DailyMed SPL version 3." Version 1, published 2026-08-22. https://peptidescanner.com/evidence/v1/peptides/tesamorelin.json#dailymed-label-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v3-v1 SHA-256: 0cc39399e8f8253c4eec414573d930731437c4a535293ca90a1ea6f072d4c4d6.

---

<a id="dailymed-label-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v4-v1"></a>

## Tesamorelin DailyMed SPL version 4

> DailyMed lists Structured Product Labeling version 4 for the reviewed Tesamorelin label family with a published date of 2022-12-26. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

- Evidence object: `story:dailymed-label-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v4:v1`
- Evidence domain: Regulatory
- Date in source: 2022-12-26
- Source checked: 2026-08-22
- Published by PeptideScanner: 2026-08-22
- Story landing page: https://peptidescanner.com/stories/dailymed-label-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v4/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tesamorelin.json#dailymed-label-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v4-v1
- Content SHA-256: `7cc3ddfa18fb619a0e239580544721be40182db8d614ab83f93ff2e79a10d7f3`

### Claims and source pins

#### Headline

Tesamorelin DailyMed SPL version 4 ([`dailymed-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v4-history`](#source-dailymed-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v4-history))

#### Summary

DailyMed lists Structured Product Labeling version 4 for the reviewed Tesamorelin label family with a published date of 2022-12-26. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v4-history`](#source-dailymed-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v4-history))

#### Paragraph 1

DailyMed lists Structured Product Labeling version 4 for the reviewed Tesamorelin label family with a published date of 2022-12-26. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v4-history`](#source-dailymed-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v4-history))

#### Paragraph 2

This page reports that DailyMed lists an available Structured Product Labeling version for the reviewed label family and links the exact historical ZIP. It does not reproduce label text, identify which sections changed, establish FDA approval, interpret safety or effectiveness, or provide medical guidance. ([`dailymed-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v4-history`](#source-dailymed-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v4-history))

### Sources

<a id="source-dailymed-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v4-history"></a>
- **DailyMed SPL SET ID 3d783378-b02d-4f19-99dd-0fc91a042224 · SPL version 4 · published 2022-12-26 · retained ZIP SHA-256 b8f7b9154d56de66a16d5a20eeb569fa3a49dc68a7034f39a05793ab0fea060a** — DailyMed · U.S. National Library of Medicine; class A. [Open source](https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=3d783378-b02d-4f19-99dd-0fc91a042224&version=4) (`dailymed-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v4-history`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Tesamorelin DailyMed SPL version 4." Version 1, published 2026-08-22. https://peptidescanner.com/evidence/v1/peptides/tesamorelin.json#dailymed-label-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v4-v1 SHA-256: 7cc3ddfa18fb619a0e239580544721be40182db8d614ab83f93ff2e79a10d7f3.

---

<a id="dailymed-label-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v5-v1"></a>

## Tesamorelin DailyMed SPL version 5

> DailyMed lists Structured Product Labeling version 5 for the reviewed Tesamorelin label family with a published date of 2024-02-02. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

- Evidence object: `story:dailymed-label-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v5:v1`
- Evidence domain: Regulatory
- Date in source: 2024-02-02
- Source checked: 2026-08-22
- Published by PeptideScanner: 2026-08-22
- Story landing page: https://peptidescanner.com/stories/dailymed-label-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v5/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tesamorelin.json#dailymed-label-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v5-v1
- Content SHA-256: `c2bf77c207ec6f6d42b12398409855146d6c7fcbbdfc0b3501ed7c44a87e56e2`

### Claims and source pins

#### Headline

Tesamorelin DailyMed SPL version 5 ([`dailymed-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v5-history`](#source-dailymed-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v5-history))

#### Summary

DailyMed lists Structured Product Labeling version 5 for the reviewed Tesamorelin label family with a published date of 2024-02-02. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v5-history`](#source-dailymed-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v5-history))

#### Paragraph 1

DailyMed lists Structured Product Labeling version 5 for the reviewed Tesamorelin label family with a published date of 2024-02-02. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v5-history`](#source-dailymed-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v5-history))

#### Paragraph 2

This page reports that DailyMed lists an available Structured Product Labeling version for the reviewed label family and links the exact historical ZIP. It does not reproduce label text, identify which sections changed, establish FDA approval, interpret safety or effectiveness, or provide medical guidance. ([`dailymed-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v5-history`](#source-dailymed-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v5-history))

### Sources

<a id="source-dailymed-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v5-history"></a>
- **DailyMed SPL SET ID 3d783378-b02d-4f19-99dd-0fc91a042224 · SPL version 5 · published 2024-02-02 · retained ZIP SHA-256 7d01258ee9daf596fef6e4a5f78ab4a8bb4fa9e00761d6ab42743800914351b6** — DailyMed · U.S. National Library of Medicine; class A. [Open source](https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=3d783378-b02d-4f19-99dd-0fc91a042224&version=5) (`dailymed-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v5-history`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Tesamorelin DailyMed SPL version 5." Version 1, published 2026-08-22. https://peptidescanner.com/evidence/v1/peptides/tesamorelin.json#dailymed-label-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v5-v1 SHA-256: c2bf77c207ec6f6d42b12398409855146d6c7fcbbdfc0b3501ed7c44a87e56e2.

---

<a id="dailymed-label-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v6-v1"></a>

## Tesamorelin DailyMed SPL version 6

> DailyMed lists Structured Product Labeling version 6 for the reviewed Tesamorelin label family with a published date of 2024-03-14. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

- Evidence object: `story:dailymed-label-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v6:v1`
- Evidence domain: Regulatory
- Date in source: 2024-03-14
- Source checked: 2026-08-22
- Published by PeptideScanner: 2026-08-22
- Story landing page: https://peptidescanner.com/stories/dailymed-label-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v6/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tesamorelin.json#dailymed-label-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v6-v1
- Content SHA-256: `15202ef00978ac3de12f88299d69a03d967392ad8ddbc3c771bd3820d61b08c9`

### Claims and source pins

#### Headline

Tesamorelin DailyMed SPL version 6 ([`dailymed-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v6-history`](#source-dailymed-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v6-history))

#### Summary

DailyMed lists Structured Product Labeling version 6 for the reviewed Tesamorelin label family with a published date of 2024-03-14. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v6-history`](#source-dailymed-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v6-history))

#### Paragraph 1

DailyMed lists Structured Product Labeling version 6 for the reviewed Tesamorelin label family with a published date of 2024-03-14. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v6-history`](#source-dailymed-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v6-history))

#### Paragraph 2

This page reports that DailyMed lists an available Structured Product Labeling version for the reviewed label family and links the exact historical ZIP. It does not reproduce label text, identify which sections changed, establish FDA approval, interpret safety or effectiveness, or provide medical guidance. ([`dailymed-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v6-history`](#source-dailymed-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v6-history))

### Sources

<a id="source-dailymed-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v6-history"></a>
- **DailyMed SPL SET ID 3d783378-b02d-4f19-99dd-0fc91a042224 · SPL version 6 · published 2024-03-14 · retained ZIP SHA-256 2bc5c98e1c1217f3046a40b16c43401ca368b5990e02e97ec5c44f670851253e** — DailyMed · U.S. National Library of Medicine; class A. [Open source](https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=3d783378-b02d-4f19-99dd-0fc91a042224&version=6) (`dailymed-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v6-history`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Tesamorelin DailyMed SPL version 6." Version 1, published 2026-08-22. https://peptidescanner.com/evidence/v1/peptides/tesamorelin.json#dailymed-label-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v6-v1 SHA-256: 15202ef00978ac3de12f88299d69a03d967392ad8ddbc3c771bd3820d61b08c9.

---

<a id="dailymed-label-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v7-v1"></a>

## Tesamorelin DailyMed SPL version 7

> DailyMed lists Structured Product Labeling version 7 for the reviewed Tesamorelin label family with a published date of 2024-12-23. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

- Evidence object: `story:dailymed-label-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v7:v1`
- Evidence domain: Regulatory
- Date in source: 2024-12-23
- Source checked: 2026-08-22
- Published by PeptideScanner: 2026-08-22
- Story landing page: https://peptidescanner.com/stories/dailymed-label-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v7/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tesamorelin.json#dailymed-label-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v7-v1
- Content SHA-256: `0a91c9b95bcbc812465c100d37ccc2194eac1e05c33594635a78423343371358`

### Claims and source pins

#### Headline

Tesamorelin DailyMed SPL version 7 ([`dailymed-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v7-history`](#source-dailymed-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v7-history))

#### Summary

DailyMed lists Structured Product Labeling version 7 for the reviewed Tesamorelin label family with a published date of 2024-12-23. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v7-history`](#source-dailymed-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v7-history))

#### Paragraph 1

DailyMed lists Structured Product Labeling version 7 for the reviewed Tesamorelin label family with a published date of 2024-12-23. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v7-history`](#source-dailymed-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v7-history))

#### Paragraph 2

This page reports that DailyMed lists an available Structured Product Labeling version for the reviewed label family and links the exact historical ZIP. It does not reproduce label text, identify which sections changed, establish FDA approval, interpret safety or effectiveness, or provide medical guidance. ([`dailymed-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v7-history`](#source-dailymed-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v7-history))

### Sources

<a id="source-dailymed-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v7-history"></a>
- **DailyMed SPL SET ID 3d783378-b02d-4f19-99dd-0fc91a042224 · SPL version 7 · published 2024-12-23 · retained ZIP SHA-256 c6230de76ac16b46460951b30aa3e48196b1663b1b94412b4d0553af663b807c** — DailyMed · U.S. National Library of Medicine; class A. [Open source](https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=3d783378-b02d-4f19-99dd-0fc91a042224&version=7) (`dailymed-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v7-history`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Tesamorelin DailyMed SPL version 7." Version 1, published 2026-08-22. https://peptidescanner.com/evidence/v1/peptides/tesamorelin.json#dailymed-label-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v7-v1 SHA-256: 0a91c9b95bcbc812465c100d37ccc2194eac1e05c33594635a78423343371358.

---

<a id="dailymed-label-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v8-v1"></a>

## Tesamorelin DailyMed SPL version 8

> DailyMed lists Structured Product Labeling version 8 for the reviewed Tesamorelin label family with a published date of 2026-01-02. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

- Evidence object: `story:dailymed-label-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v8:v1`
- Evidence domain: Regulatory
- Date in source: 2026-01-02
- Source checked: 2026-08-22
- Published by PeptideScanner: 2026-08-22
- Story landing page: https://peptidescanner.com/stories/dailymed-label-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v8/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tesamorelin.json#dailymed-label-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v8-v1
- Content SHA-256: `0eaff4238ded88ef4aa4ae94f3bfa0f2fbfc496a672ebd2d795448a12548310b`

### Claims and source pins

#### Headline

Tesamorelin DailyMed SPL version 8 ([`dailymed-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v8-history`](#source-dailymed-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v8-history))

#### Summary

DailyMed lists Structured Product Labeling version 8 for the reviewed Tesamorelin label family with a published date of 2026-01-02. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v8-history`](#source-dailymed-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v8-history))

#### Paragraph 1

DailyMed lists Structured Product Labeling version 8 for the reviewed Tesamorelin label family with a published date of 2026-01-02. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v8-history`](#source-dailymed-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v8-history))

#### Paragraph 2

This page reports that DailyMed lists an available Structured Product Labeling version for the reviewed label family and links the exact historical ZIP. It does not reproduce label text, identify which sections changed, establish FDA approval, interpret safety or effectiveness, or provide medical guidance. ([`dailymed-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v8-history`](#source-dailymed-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v8-history))

### Sources

<a id="source-dailymed-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v8-history"></a>
- **DailyMed SPL SET ID 3d783378-b02d-4f19-99dd-0fc91a042224 · SPL version 8 · published 2026-01-02 · retained ZIP SHA-256 93ebb09e6ddb129ec6791039b16cd29976c982cba93bf929b4693697590a49d5** — DailyMed · U.S. National Library of Medicine; class A. [Open source](https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=3d783378-b02d-4f19-99dd-0fc91a042224&version=8) (`dailymed-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v8-history`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Tesamorelin DailyMed SPL version 8." Version 1, published 2026-08-22. https://peptidescanner.com/evidence/v1/peptides/tesamorelin.json#dailymed-label-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v8-v1 SHA-256: 0eaff4238ded88ef4aa4ae94f3bfa0f2fbfc496a672ebd2d795448a12548310b.

---

<a id="dailymed-label-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v9-v1"></a>

## Tesamorelin DailyMed SPL version 9

> DailyMed lists Structured Product Labeling version 9 for the reviewed Tesamorelin label family with a published date of 2026-07-31. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

- Evidence object: `story:dailymed-label-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v9:v1`
- Evidence domain: Regulatory
- Date in source: 2026-07-31
- Source checked: 2026-08-22
- Published by PeptideScanner: 2026-08-22
- Story landing page: https://peptidescanner.com/stories/dailymed-label-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v9/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tesamorelin.json#dailymed-label-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v9-v1
- Content SHA-256: `801be987343aa145f1e3db61a83ba4b63275d44a39b4f0c275baf1df0e3218c8`

### Claims and source pins

#### Headline

Tesamorelin DailyMed SPL version 9 ([`dailymed-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v9-history`](#source-dailymed-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v9-history))

#### Summary

DailyMed lists Structured Product Labeling version 9 for the reviewed Tesamorelin label family with a published date of 2026-07-31. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v9-history`](#source-dailymed-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v9-history))

#### Paragraph 1

DailyMed lists Structured Product Labeling version 9 for the reviewed Tesamorelin label family with a published date of 2026-07-31. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v9-history`](#source-dailymed-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v9-history))

#### Paragraph 2

This page reports that DailyMed lists an available Structured Product Labeling version for the reviewed label family and links the exact historical ZIP. It does not reproduce label text, identify which sections changed, establish FDA approval, interpret safety or effectiveness, or provide medical guidance. ([`dailymed-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v9-history`](#source-dailymed-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v9-history))

### Sources

<a id="source-dailymed-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v9-history"></a>
- **DailyMed SPL SET ID 3d783378-b02d-4f19-99dd-0fc91a042224 · SPL version 9 · published 2026-07-31 · retained ZIP SHA-256 2208a57e39a937407fe40c3d00ff1f8547a7a33e87685d40205cfaba9137cc6c** — DailyMed · U.S. National Library of Medicine; class A. [Open source](https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=3d783378-b02d-4f19-99dd-0fc91a042224&version=9) (`dailymed-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v9-history`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Tesamorelin DailyMed SPL version 9." Version 1, published 2026-08-22. https://peptidescanner.com/evidence/v1/peptides/tesamorelin.json#dailymed-label-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v9-v1 SHA-256: 801be987343aa145f1e3db61a83ba4b63275d44a39b4f0c275baf1df0e3218c8.

---

<a id="fda-drugs-bla022505-v1"></a>

## Drugs@FDA application BLA022505

> The official Drugs@FDA dataset lists original submission 1 for BLA 022505 with status AP dated 2010-11-10, and names tesamorelin acetate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-bla022505:v1`
- Evidence domain: Regulatory
- Date in source: 2010-11-10
- Source checked: 2026-08-14
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/fda-drugs-bla022505/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tesamorelin.json#fda-drugs-bla022505-v1
- Content SHA-256: `b7fdcc5f447f4b9a1d9dc91d9a222db5c7547e2a3e34b9a5a6f260c0f8797630`

### Claims and source pins

#### Headline

Drugs@FDA application BLA022505 ([`fda-drugs-bla022505-2010-11-10-9cc235ae6ce0`](#source-fda-drugs-bla022505-2010-11-10-9cc235ae6ce0))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for BLA 022505 with status AP dated 2010-11-10, and names tesamorelin acetate among the application record's active ingredients. ([`fda-drugs-bla022505-2010-11-10-9cc235ae6ce0`](#source-fda-drugs-bla022505-2010-11-10-9cc235ae6ce0))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for BLA 022505 with status AP dated 2010-11-10, and names tesamorelin acetate among the application record's active ingredients. ([`fda-drugs-bla022505-2010-11-10-9cc235ae6ce0`](#source-fda-drugs-bla022505-2010-11-10-9cc235ae6ce0))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-bla022505-2010-11-10-9cc235ae6ce0`](#source-fda-drugs-bla022505-2010-11-10-9cc235ae6ce0))

### Sources

<a id="source-fda-drugs-bla022505-2010-11-10-9cc235ae6ce0"></a>
- **Drugs@FDA application BLA022505 · original submission status AP · 2010-11-10 · dataset 2026-08-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22BLA022505%22&limit=1) (`fda-drugs-bla022505-2010-11-10-9cc235ae6ce0`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application BLA022505." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/tesamorelin.json#fda-drugs-bla022505-v1 SHA-256: b7fdcc5f447f4b9a1d9dc91d9a222db5c7547e2a3e34b9a5a6f260c0f8797630.

---

<a id="federal-register-2010-6169-v1"></a>

## Federal Register notice 2010-6169

> The Federal Register published notice 2010-6169, attributed to FDA and its parent HHS department, on 2010-03-22. Its official title is “Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Tesamorelin.

- Evidence object: `story:federal-register-2010-6169:v1`
- Evidence domain: Regulatory
- Date in source: 2010-03-22
- Source checked: 2026-08-21
- Published by PeptideScanner: 2026-08-21
- Story landing page: https://peptidescanner.com/stories/federal-register-2010-6169/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tesamorelin.json#federal-register-2010-6169-v1
- Content SHA-256: `75ebb14524d67c8545698452a7c73bf6a34de80efbee343eb8ea676fa71db189`

### Claims and source pins

#### Headline

Federal Register notice 2010-6169 ([`federal-register-2010-6169-ab9dc10cb205`](#source-federal-register-2010-6169-ab9dc10cb205))

#### Summary

The Federal Register published notice 2010-6169, attributed to FDA and its parent HHS department, on 2010-03-22. Its official title is “Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Tesamorelin. ([`federal-register-2010-6169-ab9dc10cb205`](#source-federal-register-2010-6169-ab9dc10cb205))

#### Paragraph 1

The Federal Register published notice 2010-6169, attributed to FDA and its parent HHS department, on 2010-03-22. Its official title is “Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Tesamorelin. ([`federal-register-2010-6169-ab9dc10cb205`](#source-federal-register-2010-6169-ab9dc10cb205))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-2010-6169-ab9dc10cb205`](#source-federal-register-2010-6169-ab9dc10cb205))

### Sources

<a id="source-federal-register-2010-6169-ab9dc10cb205"></a>
- **Federal Register notice 2010-6169 · published 2010-03-22 · Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Meeting** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2010-03-22/pdf/2010-6169.pdf) (`federal-register-2010-6169-ab9dc10cb205`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice 2010-6169." Version 1, published 2026-08-21. https://peptidescanner.com/evidence/v1/peptides/tesamorelin.json#federal-register-2010-6169-v1 SHA-256: 75ebb14524d67c8545698452a7c73bf6a34de80efbee343eb8ea676fa71db189.

---

<a id="federal-register-2010-785-v1"></a>

## Federal Register notice 2010-785

> The Federal Register published notice 2010-785, attributed to FDA and its parent HHS department, on 2010-01-19. Its official title is “Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Tesamorelin.

- Evidence object: `story:federal-register-2010-785:v1`
- Evidence domain: Regulatory
- Date in source: 2010-01-19
- Source checked: 2026-08-21
- Published by PeptideScanner: 2026-08-21
- Story landing page: https://peptidescanner.com/stories/federal-register-2010-785/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tesamorelin.json#federal-register-2010-785-v1
- Content SHA-256: `4a08f565ea5c2c756982706a68056533767aa755437e7b4c88d3bb109a825712`

### Claims and source pins

#### Headline

Federal Register notice 2010-785 ([`federal-register-2010-785-9b284ae52771`](#source-federal-register-2010-785-9b284ae52771))

#### Summary

The Federal Register published notice 2010-785, attributed to FDA and its parent HHS department, on 2010-01-19. Its official title is “Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Tesamorelin. ([`federal-register-2010-785-9b284ae52771`](#source-federal-register-2010-785-9b284ae52771))

#### Paragraph 1

The Federal Register published notice 2010-785, attributed to FDA and its parent HHS department, on 2010-01-19. Its official title is “Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Tesamorelin. ([`federal-register-2010-785-9b284ae52771`](#source-federal-register-2010-785-9b284ae52771))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-2010-785-9b284ae52771`](#source-federal-register-2010-785-9b284ae52771))

### Sources

<a id="source-federal-register-2010-785-9b284ae52771"></a>
- **Federal Register notice 2010-785 · published 2010-01-19 · Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Meeting** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2010-01-19/pdf/2010-785.pdf) (`federal-register-2010-785-9b284ae52771`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice 2010-785." Version 1, published 2026-08-21. https://peptidescanner.com/evidence/v1/peptides/tesamorelin.json#federal-register-2010-785-v1 SHA-256: 4a08f565ea5c2c756982706a68056533767aa755437e7b4c88d3bb109a825712.

---

<a id="federal-register-2012-10808-v1"></a>

## Federal Register notice 2012-10808

> The Federal Register published notice 2012-10808, attributed to FDA and its parent HHS department, on 2012-05-04. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; EGRIFTA,” and PeptideScanner's exact reviewed identity mapping connects the document to Tesamorelin.

- Evidence object: `story:federal-register-2012-10808:v1`
- Evidence domain: Regulatory
- Date in source: 2012-05-04
- Source checked: 2026-08-21
- Published by PeptideScanner: 2026-08-21
- Story landing page: https://peptidescanner.com/stories/federal-register-2012-10808/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tesamorelin.json#federal-register-2012-10808-v1
- Content SHA-256: `24f8494a26cb91a7a463f9482c6472ba5db9df60d1bc5035ee0f2281326a4f9a`

### Claims and source pins

#### Headline

Federal Register notice 2012-10808 ([`federal-register-2012-10808-802554650609`](#source-federal-register-2012-10808-802554650609))

#### Summary

The Federal Register published notice 2012-10808, attributed to FDA and its parent HHS department, on 2012-05-04. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; EGRIFTA,” and PeptideScanner's exact reviewed identity mapping connects the document to Tesamorelin. ([`federal-register-2012-10808-802554650609`](#source-federal-register-2012-10808-802554650609))

#### Paragraph 1

The Federal Register published notice 2012-10808, attributed to FDA and its parent HHS department, on 2012-05-04. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; EGRIFTA,” and PeptideScanner's exact reviewed identity mapping connects the document to Tesamorelin. ([`federal-register-2012-10808-802554650609`](#source-federal-register-2012-10808-802554650609))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-2012-10808-802554650609`](#source-federal-register-2012-10808-802554650609))

### Sources

<a id="source-federal-register-2012-10808-802554650609"></a>
- **Federal Register notice 2012-10808 · published 2012-05-04 · Determination of Regulatory Review Period for Purposes of Patent Extension; EGRIFTA** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2012-05-04/pdf/2012-10808.pdf) (`federal-register-2012-10808-802554650609`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice 2012-10808." Version 1, published 2026-08-21. https://peptidescanner.com/evidence/v1/peptides/tesamorelin.json#federal-register-2012-10808-v1 SHA-256: 24f8494a26cb91a7a463f9482c6472ba5db9df60d1bc5035ee0f2281326a4f9a.

---

<a id="pubmed-pmid-17571443-tesamorelin-v1"></a>

## PubMed record PMID 17571443

> PeptideScanner retained PubMed bibliographic metadata for PMID 17571443 at 2026-07-30T16:30:45.652Z. PubMed recorded a metadata revision date of 2026-01-28 and an Entrez history date of 2007-06-19. PeptideScanner associated this retained record with the identity slug tesamorelin. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-17571443-tesamorelin:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-01-28
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-17571443-tesamorelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tesamorelin.json#pubmed-pmid-17571443-tesamorelin-v1
- Content SHA-256: `a4047b19a86dbb511c095652cead5d0186784cac33bd9f0e418755f169f46998`

### Claims and source pins

#### Headline

PubMed record PMID 17571443 ([`pubmed-observation-pmid-17571443-2026-01-28-c464a5a138fc`](#source-pubmed-observation-pmid-17571443-2026-01-28-c464a5a138fc))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 17571443 at 2026-07-30T16:30:45.652Z. PubMed recorded a metadata revision date of 2026-01-28 and an Entrez history date of 2007-06-19. PeptideScanner associated this retained record with the identity slug tesamorelin. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-17571443-2026-01-28-c464a5a138fc`](#source-pubmed-observation-pmid-17571443-2026-01-28-c464a5a138fc))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 17571443 at 2026-07-30T16:30:45.652Z. PubMed recorded a metadata revision date of 2026-01-28 and an Entrez history date of 2007-06-19. PeptideScanner associated this retained record with the identity slug tesamorelin. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-17571443-2026-01-28-c464a5a138fc`](#source-pubmed-observation-pmid-17571443-2026-01-28-c464a5a138fc))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-17571443-2026-01-28-c464a5a138fc`](#source-pubmed-observation-pmid-17571443-2026-01-28-c464a5a138fc))

### Sources

<a id="source-pubmed-observation-pmid-17571443-2026-01-28-c464a5a138fc"></a>
- **PubMed record PMID 17571443 · retained source version 1:2026-01-28:current:c464a5a138fc8cfd8edae6fcc473223b00cf2950436e88ae44f381eaa4f9dd26** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/17571443/) (`pubmed-observation-pmid-17571443-2026-01-28-c464a5a138fc`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 17571443." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/tesamorelin.json#pubmed-pmid-17571443-tesamorelin-v1 SHA-256: a4047b19a86dbb511c095652cead5d0186784cac33bd9f0e418755f169f46998.

---

<a id="pubmed-pmid-17575575-tesamorelin-v1"></a>

## PubMed record PMID 17575575

> PeptideScanner retained PubMed bibliographic metadata for PMID 17575575 at 2026-07-30T21:22:56.977Z. PubMed recorded a metadata revision date of 2017-11-16 and an Entrez history date of 2007-06-19. PeptideScanner associated this retained record with the identity slug tesamorelin. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-17575575-tesamorelin:v1`
- Evidence domain: Literature metadata
- Date in source: 2017-11-16
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-11
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-17575575-tesamorelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tesamorelin.json#pubmed-pmid-17575575-tesamorelin-v1
- Content SHA-256: `6d0d4298df40cea49d3a061a0808d662dd95c01b42e1e9a4630a9d270a042e51`

### Claims and source pins

#### Headline

PubMed record PMID 17575575 ([`pubmed-observation-pmid-17575575-2017-11-16-a2604f24cbbe`](#source-pubmed-observation-pmid-17575575-2017-11-16-a2604f24cbbe))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 17575575 at 2026-07-30T21:22:56.977Z. PubMed recorded a metadata revision date of 2017-11-16 and an Entrez history date of 2007-06-19. PeptideScanner associated this retained record with the identity slug tesamorelin. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-17575575-2017-11-16-a2604f24cbbe`](#source-pubmed-observation-pmid-17575575-2017-11-16-a2604f24cbbe))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 17575575 at 2026-07-30T21:22:56.977Z. PubMed recorded a metadata revision date of 2017-11-16 and an Entrez history date of 2007-06-19. PeptideScanner associated this retained record with the identity slug tesamorelin. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-17575575-2017-11-16-a2604f24cbbe`](#source-pubmed-observation-pmid-17575575-2017-11-16-a2604f24cbbe))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-17575575-2017-11-16-a2604f24cbbe`](#source-pubmed-observation-pmid-17575575-2017-11-16-a2604f24cbbe))

### Sources

<a id="source-pubmed-observation-pmid-17575575-2017-11-16-a2604f24cbbe"></a>
- **PubMed record PMID 17575575 · retained source version 1:2017-11-16:current:a2604f24cbbe10aa63022f0afae82ffe1df59145c367bab1c1924f36152b43c1** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/17575575/) (`pubmed-observation-pmid-17575575-2017-11-16-a2604f24cbbe`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 17575575." Version 1, published 2026-08-11. https://peptidescanner.com/evidence/v1/peptides/tesamorelin.json#pubmed-pmid-17575575-tesamorelin-v1 SHA-256: 6d0d4298df40cea49d3a061a0808d662dd95c01b42e1e9a4630a9d270a042e51.

---

<a id="pubmed-pmid-18690162-tesamorelin-v1"></a>

## PubMed record PMID 18690162

> PeptideScanner retained PubMed bibliographic metadata for PMID 18690162 at 2026-07-30T21:22:56.979Z. PubMed recorded a metadata revision date of 2017-11-16 and an Entrez history date of 2008-08-12. PeptideScanner associated this retained record with the identity slug tesamorelin. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-18690162-tesamorelin:v1`
- Evidence domain: Literature metadata
- Date in source: 2017-11-16
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-11
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-18690162-tesamorelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tesamorelin.json#pubmed-pmid-18690162-tesamorelin-v1
- Content SHA-256: `fb6c2f9bac2111a71a7da7935a5c6f577111c0583521ea9e64a3e3b76f6f5337`

### Claims and source pins

#### Headline

PubMed record PMID 18690162 ([`pubmed-observation-pmid-18690162-2017-11-16-7273e978a45c`](#source-pubmed-observation-pmid-18690162-2017-11-16-7273e978a45c))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 18690162 at 2026-07-30T21:22:56.979Z. PubMed recorded a metadata revision date of 2017-11-16 and an Entrez history date of 2008-08-12. PeptideScanner associated this retained record with the identity slug tesamorelin. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-18690162-2017-11-16-7273e978a45c`](#source-pubmed-observation-pmid-18690162-2017-11-16-7273e978a45c))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 18690162 at 2026-07-30T21:22:56.979Z. PubMed recorded a metadata revision date of 2017-11-16 and an Entrez history date of 2008-08-12. PeptideScanner associated this retained record with the identity slug tesamorelin. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-18690162-2017-11-16-7273e978a45c`](#source-pubmed-observation-pmid-18690162-2017-11-16-7273e978a45c))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-18690162-2017-11-16-7273e978a45c`](#source-pubmed-observation-pmid-18690162-2017-11-16-7273e978a45c))

### Sources

<a id="source-pubmed-observation-pmid-18690162-2017-11-16-7273e978a45c"></a>
- **PubMed record PMID 18690162 · retained source version 1:2017-11-16:current:7273e978a45c2c79e5b9494b60b0dae7e2a7a7046ce9c184f573ef7d17996fb5** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/18690162/) (`pubmed-observation-pmid-18690162-2017-11-16-7273e978a45c`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 18690162." Version 1, published 2026-08-11. https://peptidescanner.com/evidence/v1/peptides/tesamorelin.json#pubmed-pmid-18690162-tesamorelin-v1 SHA-256: fb6c2f9bac2111a71a7da7935a5c6f577111c0583521ea9e64a3e3b76f6f5337.

---

<a id="pubmed-pmid-18724445-tesamorelin-v1"></a>

## PubMed record PMID 18724445

> PeptideScanner retained PubMed bibliographic metadata for PMID 18724445 at 2026-07-30T21:22:56.979Z. PubMed recorded a metadata revision date of 2017-11-16 and an Entrez history date of 2008-08-30. PeptideScanner associated this retained record with the identity slug tesamorelin. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-18724445-tesamorelin:v1`
- Evidence domain: Literature metadata
- Date in source: 2017-11-16
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-11
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-18724445-tesamorelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tesamorelin.json#pubmed-pmid-18724445-tesamorelin-v1
- Content SHA-256: `43760685a663cb175a1f472d701e1e728c252deb1d5281be79265a3e36d8b6cb`

### Claims and source pins

#### Headline

PubMed record PMID 18724445 ([`pubmed-observation-pmid-18724445-2017-11-16-daf5b16cb44a`](#source-pubmed-observation-pmid-18724445-2017-11-16-daf5b16cb44a))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 18724445 at 2026-07-30T21:22:56.979Z. PubMed recorded a metadata revision date of 2017-11-16 and an Entrez history date of 2008-08-30. PeptideScanner associated this retained record with the identity slug tesamorelin. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-18724445-2017-11-16-daf5b16cb44a`](#source-pubmed-observation-pmid-18724445-2017-11-16-daf5b16cb44a))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 18724445 at 2026-07-30T21:22:56.979Z. PubMed recorded a metadata revision date of 2017-11-16 and an Entrez history date of 2008-08-30. PeptideScanner associated this retained record with the identity slug tesamorelin. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-18724445-2017-11-16-daf5b16cb44a`](#source-pubmed-observation-pmid-18724445-2017-11-16-daf5b16cb44a))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-18724445-2017-11-16-daf5b16cb44a`](#source-pubmed-observation-pmid-18724445-2017-11-16-daf5b16cb44a))

### Sources

<a id="source-pubmed-observation-pmid-18724445-2017-11-16-daf5b16cb44a"></a>
- **PubMed record PMID 18724445 · retained source version 1:2017-11-16:current:daf5b16cb44ace8123e7339e54f0f1904c48bfcd7d3b3dd44e4a79008e8855f7** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/18724445/) (`pubmed-observation-pmid-18724445-2017-11-16-daf5b16cb44a`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 18724445." Version 1, published 2026-08-11. https://peptidescanner.com/evidence/v1/peptides/tesamorelin.json#pubmed-pmid-18724445-tesamorelin-v1 SHA-256: 43760685a663cb175a1f472d701e1e728c252deb1d5281be79265a3e36d8b6cb.

---

<a id="pubmed-pmid-18828236-tesamorelin-v1"></a>

## PubMed record PMID 18828236

> PeptideScanner retained PubMed bibliographic metadata for PMID 18828236 at 2026-07-30T21:22:56.979Z. PubMed recorded a metadata revision date of 2017-11-16 and an Entrez history date of 2008-10-03. PeptideScanner associated this retained record with the identity slug tesamorelin. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-18828236-tesamorelin:v1`
- Evidence domain: Literature metadata
- Date in source: 2017-11-16
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-11
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-18828236-tesamorelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tesamorelin.json#pubmed-pmid-18828236-tesamorelin-v1
- Content SHA-256: `ecd0af3b5d5dcf800a0f7931bef1fa9f71f623ee64cbd0f9e5c0f0a551957a56`

### Claims and source pins

#### Headline

PubMed record PMID 18828236 ([`pubmed-observation-pmid-18828236-2017-11-16-79c97c54c323`](#source-pubmed-observation-pmid-18828236-2017-11-16-79c97c54c323))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 18828236 at 2026-07-30T21:22:56.979Z. PubMed recorded a metadata revision date of 2017-11-16 and an Entrez history date of 2008-10-03. PeptideScanner associated this retained record with the identity slug tesamorelin. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-18828236-2017-11-16-79c97c54c323`](#source-pubmed-observation-pmid-18828236-2017-11-16-79c97c54c323))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 18828236 at 2026-07-30T21:22:56.979Z. PubMed recorded a metadata revision date of 2017-11-16 and an Entrez history date of 2008-10-03. PeptideScanner associated this retained record with the identity slug tesamorelin. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-18828236-2017-11-16-79c97c54c323`](#source-pubmed-observation-pmid-18828236-2017-11-16-79c97c54c323))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-18828236-2017-11-16-79c97c54c323`](#source-pubmed-observation-pmid-18828236-2017-11-16-79c97c54c323))

### Sources

<a id="source-pubmed-observation-pmid-18828236-2017-11-16-79c97c54c323"></a>
- **PubMed record PMID 18828236 · retained source version 1:2017-11-16:current:79c97c54c323583e75957b338643e2f40e3b6b3504a4f0c7701642c2f76f4ffc** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/18828236/) (`pubmed-observation-pmid-18828236-2017-11-16-79c97c54c323`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 18828236." Version 1, published 2026-08-11. https://peptidescanner.com/evidence/v1/peptides/tesamorelin.json#pubmed-pmid-18828236-tesamorelin-v1 SHA-256: ecd0af3b5d5dcf800a0f7931bef1fa9f71f623ee64cbd0f9e5c0f0a551957a56.

---

<a id="pubmed-pmid-19243281-tesamorelin-v1"></a>

## PubMed record PMID 19243281

> PeptideScanner retained PubMed bibliographic metadata for PMID 19243281 at 2026-07-30T20:47:02.486Z. PubMed recorded a metadata revision date of 2019-09-17 and an Entrez history date of 2009-02-27. PeptideScanner associated this retained record with the identity slug tesamorelin. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-19243281-tesamorelin:v1`
- Evidence domain: Literature metadata
- Date in source: 2019-09-17
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-19243281-tesamorelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tesamorelin.json#pubmed-pmid-19243281-tesamorelin-v1
- Content SHA-256: `a02725f0c469c42ebe7904c28b62b22ffb402c5c2d8e535b0361741089f1781a`

### Claims and source pins

#### Headline

PubMed record PMID 19243281 ([`pubmed-observation-pmid-19243281-2019-09-17-95dbf12c2cde`](#source-pubmed-observation-pmid-19243281-2019-09-17-95dbf12c2cde))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 19243281 at 2026-07-30T20:47:02.486Z. PubMed recorded a metadata revision date of 2019-09-17 and an Entrez history date of 2009-02-27. PeptideScanner associated this retained record with the identity slug tesamorelin. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-19243281-2019-09-17-95dbf12c2cde`](#source-pubmed-observation-pmid-19243281-2019-09-17-95dbf12c2cde))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 19243281 at 2026-07-30T20:47:02.486Z. PubMed recorded a metadata revision date of 2019-09-17 and an Entrez history date of 2009-02-27. PeptideScanner associated this retained record with the identity slug tesamorelin. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-19243281-2019-09-17-95dbf12c2cde`](#source-pubmed-observation-pmid-19243281-2019-09-17-95dbf12c2cde))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-19243281-2019-09-17-95dbf12c2cde`](#source-pubmed-observation-pmid-19243281-2019-09-17-95dbf12c2cde))

### Sources

<a id="source-pubmed-observation-pmid-19243281-2019-09-17-95dbf12c2cde"></a>
- **PubMed record PMID 19243281 · retained source version 1:2019-09-17:current:95dbf12c2cde9bd6bc44b1f19832f09ac8d9bc9ece6ef4f37cef32cc8ee3989d** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/19243281/) (`pubmed-observation-pmid-19243281-2019-09-17-95dbf12c2cde`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 19243281." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/tesamorelin.json#pubmed-pmid-19243281-tesamorelin-v1 SHA-256: a02725f0c469c42ebe7904c28b62b22ffb402c5c2d8e535b0361741089f1781a.

---

<a id="pubmed-pmid-21115997-tesamorelin-v1"></a>

## PubMed record PMID 21115997

> PeptideScanner retained PubMed bibliographic metadata for PMID 21115997 at 2026-07-30T16:30:48.398Z. PubMed recorded a metadata revision date of 2026-01-28 and an Entrez history date of 2010-12-01. PeptideScanner associated this retained record with the identity slug tesamorelin. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-21115997-tesamorelin:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-01-28
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-21115997-tesamorelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tesamorelin.json#pubmed-pmid-21115997-tesamorelin-v1
- Content SHA-256: `240bcd5edbc579466bb1f6a0ce8961f4b83736b1d3c4dcc1202fc83eea8b9084`

### Claims and source pins

#### Headline

PubMed record PMID 21115997 ([`pubmed-observation-pmid-21115997-2026-01-28-3e1e607998bf`](#source-pubmed-observation-pmid-21115997-2026-01-28-3e1e607998bf))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 21115997 at 2026-07-30T16:30:48.398Z. PubMed recorded a metadata revision date of 2026-01-28 and an Entrez history date of 2010-12-01. PeptideScanner associated this retained record with the identity slug tesamorelin. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-21115997-2026-01-28-3e1e607998bf`](#source-pubmed-observation-pmid-21115997-2026-01-28-3e1e607998bf))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 21115997 at 2026-07-30T16:30:48.398Z. PubMed recorded a metadata revision date of 2026-01-28 and an Entrez history date of 2010-12-01. PeptideScanner associated this retained record with the identity slug tesamorelin. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-21115997-2026-01-28-3e1e607998bf`](#source-pubmed-observation-pmid-21115997-2026-01-28-3e1e607998bf))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-21115997-2026-01-28-3e1e607998bf`](#source-pubmed-observation-pmid-21115997-2026-01-28-3e1e607998bf))

### Sources

<a id="source-pubmed-observation-pmid-21115997-2026-01-28-3e1e607998bf"></a>
- **PubMed record PMID 21115997 · retained source version 1:2026-01-28:current:3e1e607998bf14b23017531243b6c6830aba4f3b50c22de213adbcb0d91f71f2** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/21115997/) (`pubmed-observation-pmid-21115997-2026-01-28-3e1e607998bf`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 21115997." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/tesamorelin.json#pubmed-pmid-21115997-tesamorelin-v1 SHA-256: 240bcd5edbc579466bb1f6a0ce8961f4b83736b1d3c4dcc1202fc83eea8b9084.

---

<a id="pubmed-pmid-21591600-tesamorelin-v1"></a>

## PubMed record PMID 21591600

> PeptideScanner retained PubMed bibliographic metadata for PMID 21591600 at 2026-07-30T16:30:48.420Z. PubMed recorded a metadata revision date of 2026-01-28 and an Entrez history date of 2011-05-20. PeptideScanner associated this retained record with the identity slug tesamorelin. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-21591600-tesamorelin:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-01-28
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-21591600-tesamorelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tesamorelin.json#pubmed-pmid-21591600-tesamorelin-v1
- Content SHA-256: `95300a97e8ccdfca705304fd1fb543a7d8cd8d5c769eeb03b2fdab0ff7c3569e`

### Claims and source pins

#### Headline

PubMed record PMID 21591600 ([`pubmed-observation-pmid-21591600-2026-01-28-7ae3e5acb133`](#source-pubmed-observation-pmid-21591600-2026-01-28-7ae3e5acb133))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 21591600 at 2026-07-30T16:30:48.420Z. PubMed recorded a metadata revision date of 2026-01-28 and an Entrez history date of 2011-05-20. PeptideScanner associated this retained record with the identity slug tesamorelin. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-21591600-2026-01-28-7ae3e5acb133`](#source-pubmed-observation-pmid-21591600-2026-01-28-7ae3e5acb133))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 21591600 at 2026-07-30T16:30:48.420Z. PubMed recorded a metadata revision date of 2026-01-28 and an Entrez history date of 2011-05-20. PeptideScanner associated this retained record with the identity slug tesamorelin. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-21591600-2026-01-28-7ae3e5acb133`](#source-pubmed-observation-pmid-21591600-2026-01-28-7ae3e5acb133))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-21591600-2026-01-28-7ae3e5acb133`](#source-pubmed-observation-pmid-21591600-2026-01-28-7ae3e5acb133))

### Sources

<a id="source-pubmed-observation-pmid-21591600-2026-01-28-7ae3e5acb133"></a>
- **PubMed record PMID 21591600 · retained source version 1:2026-01-28:current:7ae3e5acb133cf05ce7e1e56cbb4eb013aa62039d53123eef58ebf1df62a41b2** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/21591600/) (`pubmed-observation-pmid-21591600-2026-01-28-7ae3e5acb133`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 21591600." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/tesamorelin.json#pubmed-pmid-21591600-tesamorelin-v1 SHA-256: 95300a97e8ccdfca705304fd1fb543a7d8cd8d5c769eeb03b2fdab0ff7c3569e.

---

<a id="pubmed-pmid-21695284-tesamorelin-v1"></a>

## PubMed record PMID 21695284

> PeptideScanner retained PubMed bibliographic metadata for PMID 21695284 at 2026-07-30T21:09:11.482Z. PubMed recorded a metadata revision date of 2018-12-01 and an Entrez history date of 2011-06-23. PeptideScanner associated this retained record with the identity slug tesamorelin. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-21695284-tesamorelin:v1`
- Evidence domain: Literature metadata
- Date in source: 2018-12-01
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-21695284-tesamorelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tesamorelin.json#pubmed-pmid-21695284-tesamorelin-v1
- Content SHA-256: `a1f264f1462adfb5778b1b898f2a9ea3e17bc7fd9a712e05485244b24232f48e`

### Claims and source pins

#### Headline

PubMed record PMID 21695284 ([`pubmed-observation-pmid-21695284-2018-12-01-51f750863a7d`](#source-pubmed-observation-pmid-21695284-2018-12-01-51f750863a7d))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 21695284 at 2026-07-30T21:09:11.482Z. PubMed recorded a metadata revision date of 2018-12-01 and an Entrez history date of 2011-06-23. PeptideScanner associated this retained record with the identity slug tesamorelin. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-21695284-2018-12-01-51f750863a7d`](#source-pubmed-observation-pmid-21695284-2018-12-01-51f750863a7d))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 21695284 at 2026-07-30T21:09:11.482Z. PubMed recorded a metadata revision date of 2018-12-01 and an Entrez history date of 2011-06-23. PeptideScanner associated this retained record with the identity slug tesamorelin. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-21695284-2018-12-01-51f750863a7d`](#source-pubmed-observation-pmid-21695284-2018-12-01-51f750863a7d))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-21695284-2018-12-01-51f750863a7d`](#source-pubmed-observation-pmid-21695284-2018-12-01-51f750863a7d))

### Sources

<a id="source-pubmed-observation-pmid-21695284-2018-12-01-51f750863a7d"></a>
- **PubMed record PMID 21695284 · retained source version 1:2018-12-01:current:51f750863a7ddf2026e109200de5c8faf23679945a04fe956a2e04855db8b52c** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/21695284/) (`pubmed-observation-pmid-21695284-2018-12-01-51f750863a7d`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 21695284." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/tesamorelin.json#pubmed-pmid-21695284-tesamorelin-v1 SHA-256: a1f264f1462adfb5778b1b898f2a9ea3e17bc7fd9a712e05485244b24232f48e.

---

<a id="pubmed-pmid-22050344-tesamorelin-v1"></a>

## PubMed record PMID 22050344

> PeptideScanner retained PubMed bibliographic metadata for PMID 22050344 at 2026-07-30T21:22:57.978Z. PubMed recorded a metadata revision date of 2017-11-16 and an Entrez history date of 2011-11-05. PeptideScanner associated this retained record with the identity slug tesamorelin. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-22050344-tesamorelin:v1`
- Evidence domain: Literature metadata
- Date in source: 2017-11-16
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-22050344-tesamorelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tesamorelin.json#pubmed-pmid-22050344-tesamorelin-v1
- Content SHA-256: `2a0545d4ab56014331ec8d8a6e9cf45e91aa981fadd62f90ce5ea106dacadda0`

### Claims and source pins

#### Headline

PubMed record PMID 22050344 ([`pubmed-observation-pmid-22050344-2017-11-16-bbbbcfcbe5d3`](#source-pubmed-observation-pmid-22050344-2017-11-16-bbbbcfcbe5d3))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 22050344 at 2026-07-30T21:22:57.978Z. PubMed recorded a metadata revision date of 2017-11-16 and an Entrez history date of 2011-11-05. PeptideScanner associated this retained record with the identity slug tesamorelin. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-22050344-2017-11-16-bbbbcfcbe5d3`](#source-pubmed-observation-pmid-22050344-2017-11-16-bbbbcfcbe5d3))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 22050344 at 2026-07-30T21:22:57.978Z. PubMed recorded a metadata revision date of 2017-11-16 and an Entrez history date of 2011-11-05. PeptideScanner associated this retained record with the identity slug tesamorelin. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-22050344-2017-11-16-bbbbcfcbe5d3`](#source-pubmed-observation-pmid-22050344-2017-11-16-bbbbcfcbe5d3))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-22050344-2017-11-16-bbbbcfcbe5d3`](#source-pubmed-observation-pmid-22050344-2017-11-16-bbbbcfcbe5d3))

### Sources

<a id="source-pubmed-observation-pmid-22050344-2017-11-16-bbbbcfcbe5d3"></a>
- **PubMed record PMID 22050344 · retained source version 1:2017-11-16:current:bbbbcfcbe5d3029d9911e34a9a33d83c2e07e3368e93beb97d76a7179e85dda0** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/22050344/) (`pubmed-observation-pmid-22050344-2017-11-16-bbbbcfcbe5d3`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 22050344." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/tesamorelin.json#pubmed-pmid-22050344-tesamorelin-v1 SHA-256: 2a0545d4ab56014331ec8d8a6e9cf45e91aa981fadd62f90ce5ea106dacadda0.

---

<a id="pubmed-pmid-22495074-tesamorelin-v1"></a>

## PubMed record PMID 22495074

> PeptideScanner retained PubMed bibliographic metadata for PMID 22495074 at 2026-08-10T18:13:32.273Z. PubMed recorded a metadata revision date of 2026-07-26 and an Entrez history date of 2012-04-13. PeptideScanner associated this retained record with the identity slug tesamorelin. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-22495074-tesamorelin:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-26
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-10
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-22495074-tesamorelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tesamorelin.json#pubmed-pmid-22495074-tesamorelin-v1
- Content SHA-256: `03d24607aa4b14df4f11d7ddc912f3f6eb3e9a808ea8159550636ea47d12720a`

### Claims and source pins

#### Headline

PubMed record PMID 22495074 ([`pubmed-observation-pmid-22495074-2026-07-26-91efb9acdf48`](#source-pubmed-observation-pmid-22495074-2026-07-26-91efb9acdf48))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 22495074 at 2026-08-10T18:13:32.273Z. PubMed recorded a metadata revision date of 2026-07-26 and an Entrez history date of 2012-04-13. PeptideScanner associated this retained record with the identity slug tesamorelin. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-22495074-2026-07-26-91efb9acdf48`](#source-pubmed-observation-pmid-22495074-2026-07-26-91efb9acdf48))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 22495074 at 2026-08-10T18:13:32.273Z. PubMed recorded a metadata revision date of 2026-07-26 and an Entrez history date of 2012-04-13. PeptideScanner associated this retained record with the identity slug tesamorelin. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-22495074-2026-07-26-91efb9acdf48`](#source-pubmed-observation-pmid-22495074-2026-07-26-91efb9acdf48))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-22495074-2026-07-26-91efb9acdf48`](#source-pubmed-observation-pmid-22495074-2026-07-26-91efb9acdf48))

### Sources

<a id="source-pubmed-observation-pmid-22495074-2026-07-26-91efb9acdf48"></a>
- **PubMed record PMID 22495074 · retained source version 1:2026-07-26:current:91efb9acdf4891550be14a1baf8f0be46572273e76a6781f44485030a3b01552** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/22495074/) (`pubmed-observation-pmid-22495074-2026-07-26-91efb9acdf48`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 22495074." Version 1, published 2026-08-10. https://peptidescanner.com/evidence/v1/peptides/tesamorelin.json#pubmed-pmid-22495074-tesamorelin-v1 SHA-256: 03d24607aa4b14df4f11d7ddc912f3f6eb3e9a808ea8159550636ea47d12720a.

---

<a id="pubmed-pmid-25358450-tesamorelin-v1"></a>

## Population pharmacokinetic analysis of tesamorelin in HIV-infected patients and healthy subjects.

> PubMed lists PMID 25358450 in Clinical pharmacokinetics as Clinical Trial, Phase I, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2015-03 (month precision). PeptideScanner associated the retained record with the identity slug tesamorelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-25358450-tesamorelin:v1`
- Evidence domain: Literature metadata
- Date in source: 2021-10-21
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-25358450-tesamorelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tesamorelin.json#pubmed-pmid-25358450-tesamorelin-v1
- Content SHA-256: `d9cec1c90c54605c221a8247f51fdbed86c6591c757682da3e252a13dd7db451`

### Claims and source pins

#### Headline

Population pharmacokinetic analysis of tesamorelin in HIV-infected patients and healthy subjects. ([`pubmed-observation-pmid-25358450-2021-10-21-04a54e9cf404`](#source-pubmed-observation-pmid-25358450-2021-10-21-04a54e9cf404))

#### Summary

PubMed lists PMID 25358450 in Clinical pharmacokinetics as Clinical Trial, Phase I, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2015-03 (month precision). PeptideScanner associated the retained record with the identity slug tesamorelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-25358450-2021-10-21-04a54e9cf404`](#source-pubmed-observation-pmid-25358450-2021-10-21-04a54e9cf404))

#### Paragraph 1

PubMed lists PMID 25358450 in Clinical pharmacokinetics as Clinical Trial, Phase I, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2015-03 (month precision). PeptideScanner associated the retained record with the identity slug tesamorelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-25358450-2021-10-21-04a54e9cf404`](#source-pubmed-observation-pmid-25358450-2021-10-21-04a54e9cf404))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-25358450-2021-10-21-04a54e9cf404`](#source-pubmed-observation-pmid-25358450-2021-10-21-04a54e9cf404))

### Sources

<a id="source-pubmed-observation-pmid-25358450-2021-10-21-04a54e9cf404"></a>
- **Population pharmacokinetic analysis of tesamorelin in HIV-infected patients and healthy subjects. · retained source version 1:2021-10-21:current:04a54e9cf404d6285e0ec8cffd340fa2780303f0bf8ba4a775cd16581b75403b** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/25358450/) (`pubmed-observation-pmid-25358450-2021-10-21-04a54e9cf404`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Population pharmacokinetic analysis of tesamorelin in HIV-infected patients and healthy subjects." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/tesamorelin.json#pubmed-pmid-25358450-tesamorelin-v1 SHA-256: d9cec1c90c54605c221a8247f51fdbed86c6591c757682da3e252a13dd7db451.

---

<a id="pubmed-pmid-25895899-tesamorelin-v1"></a>

## PubMed record PMID 25895899

> PeptideScanner retained PubMed bibliographic metadata for PMID 25895899 at 2026-07-30T21:09:16.102Z. PubMed recorded a metadata revision date of 2018-11-13 and an Entrez history date of 2015-04-22. PeptideScanner associated this retained record with the identity slug tesamorelin. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-25895899-tesamorelin:v1`
- Evidence domain: Literature metadata
- Date in source: 2018-11-13
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-25895899-tesamorelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tesamorelin.json#pubmed-pmid-25895899-tesamorelin-v1
- Content SHA-256: `a405b190460a0833e4b00d7c21fe57e4d9551b1a770a244faa8543b32dea32ea`

### Claims and source pins

#### Headline

PubMed record PMID 25895899 ([`pubmed-observation-pmid-25895899-2018-11-13-b6cec5e18781`](#source-pubmed-observation-pmid-25895899-2018-11-13-b6cec5e18781))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 25895899 at 2026-07-30T21:09:16.102Z. PubMed recorded a metadata revision date of 2018-11-13 and an Entrez history date of 2015-04-22. PeptideScanner associated this retained record with the identity slug tesamorelin. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-25895899-2018-11-13-b6cec5e18781`](#source-pubmed-observation-pmid-25895899-2018-11-13-b6cec5e18781))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 25895899 at 2026-07-30T21:09:16.102Z. PubMed recorded a metadata revision date of 2018-11-13 and an Entrez history date of 2015-04-22. PeptideScanner associated this retained record with the identity slug tesamorelin. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-25895899-2018-11-13-b6cec5e18781`](#source-pubmed-observation-pmid-25895899-2018-11-13-b6cec5e18781))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-25895899-2018-11-13-b6cec5e18781`](#source-pubmed-observation-pmid-25895899-2018-11-13-b6cec5e18781))

### Sources

<a id="source-pubmed-observation-pmid-25895899-2018-11-13-b6cec5e18781"></a>
- **PubMed record PMID 25895899 · retained source version 1:2018-11-13:current:b6cec5e18781bbb2c6b95f3f05085532da2bbabce78450541749b035f38f6e28** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/25895899/) (`pubmed-observation-pmid-25895899-2018-11-13-b6cec5e18781`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 25895899." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/tesamorelin.json#pubmed-pmid-25895899-tesamorelin-v1 SHA-256: a405b190460a0833e4b00d7c21fe57e4d9551b1a770a244faa8543b32dea32ea.

---

<a id="pubmed-pmid-27121785-tesamorelin-v1"></a>

## PubMed record PMID 27121785

> PeptideScanner retained PubMed bibliographic metadata for PMID 27121785 at 2026-07-30T21:38:23.144Z. PubMed recorded a metadata revision date of 2016-04-28 and an Entrez history date of 2016-04-29. PeptideScanner associated this retained record with the identity slug tesamorelin. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-27121785-tesamorelin:v1`
- Evidence domain: Literature metadata
- Date in source: 2016-04-28
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-10
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-27121785-tesamorelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tesamorelin.json#pubmed-pmid-27121785-tesamorelin-v1
- Content SHA-256: `d8e8c132572a5ab76990824ff57e1ae9295dd409f72022fc79b1a81df253aebd`

### Claims and source pins

#### Headline

PubMed record PMID 27121785 ([`pubmed-observation-pmid-27121785-2016-04-28-d86f368c944e`](#source-pubmed-observation-pmid-27121785-2016-04-28-d86f368c944e))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 27121785 at 2026-07-30T21:38:23.144Z. PubMed recorded a metadata revision date of 2016-04-28 and an Entrez history date of 2016-04-29. PeptideScanner associated this retained record with the identity slug tesamorelin. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-27121785-2016-04-28-d86f368c944e`](#source-pubmed-observation-pmid-27121785-2016-04-28-d86f368c944e))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 27121785 at 2026-07-30T21:38:23.144Z. PubMed recorded a metadata revision date of 2016-04-28 and an Entrez history date of 2016-04-29. PeptideScanner associated this retained record with the identity slug tesamorelin. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-27121785-2016-04-28-d86f368c944e`](#source-pubmed-observation-pmid-27121785-2016-04-28-d86f368c944e))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-27121785-2016-04-28-d86f368c944e`](#source-pubmed-observation-pmid-27121785-2016-04-28-d86f368c944e))

### Sources

<a id="source-pubmed-observation-pmid-27121785-2016-04-28-d86f368c944e"></a>
- **PubMed record PMID 27121785 · retained source version 1:2016-04-28:current:d86f368c944e854899256692f595c0853605c23b9f51fe9d1d79b3b3e7284ac4** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/27121785/) (`pubmed-observation-pmid-27121785-2016-04-28-d86f368c944e`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 27121785." Version 1, published 2026-08-10. https://peptidescanner.com/evidence/v1/peptides/tesamorelin.json#pubmed-pmid-27121785-tesamorelin-v1 SHA-256: d8e8c132572a5ab76990824ff57e1ae9295dd409f72022fc79b1a81df253aebd.

---

<a id="pubmed-pmid-28832410-tesamorelin-v1"></a>

## PubMed record PMID 28832410

> PeptideScanner retained PubMed bibliographic metadata for PMID 28832410 at 2026-07-30T21:09:26.816Z. PubMed recorded a metadata revision date of 2018-11-13 and an Entrez history date of 2017-08-24. PeptideScanner associated this retained record with the identity slug tesamorelin. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-28832410-tesamorelin:v1`
- Evidence domain: Literature metadata
- Date in source: 2018-11-13
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-28832410-tesamorelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tesamorelin.json#pubmed-pmid-28832410-tesamorelin-v1
- Content SHA-256: `ddb7f9d00e6b5a47393887378787c1c9c37784add5ee8a77b8c78abe1fd24856`

### Claims and source pins

#### Headline

PubMed record PMID 28832410 ([`pubmed-observation-pmid-28832410-2018-11-13-e68871cefd8c`](#source-pubmed-observation-pmid-28832410-2018-11-13-e68871cefd8c))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 28832410 at 2026-07-30T21:09:26.816Z. PubMed recorded a metadata revision date of 2018-11-13 and an Entrez history date of 2017-08-24. PeptideScanner associated this retained record with the identity slug tesamorelin. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-28832410-2018-11-13-e68871cefd8c`](#source-pubmed-observation-pmid-28832410-2018-11-13-e68871cefd8c))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 28832410 at 2026-07-30T21:09:26.816Z. PubMed recorded a metadata revision date of 2018-11-13 and an Entrez history date of 2017-08-24. PeptideScanner associated this retained record with the identity slug tesamorelin. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-28832410-2018-11-13-e68871cefd8c`](#source-pubmed-observation-pmid-28832410-2018-11-13-e68871cefd8c))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-28832410-2018-11-13-e68871cefd8c`](#source-pubmed-observation-pmid-28832410-2018-11-13-e68871cefd8c))

### Sources

<a id="source-pubmed-observation-pmid-28832410-2018-11-13-e68871cefd8c"></a>
- **PubMed record PMID 28832410 · retained source version 1:2018-11-13:current:e68871cefd8ca9a3d9d0a9f67adf42bde243e3138315a48fafbfec416f88f6df** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/28832410/) (`pubmed-observation-pmid-28832410-2018-11-13-e68871cefd8c`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 28832410." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/tesamorelin.json#pubmed-pmid-28832410-tesamorelin-v1 SHA-256: ddb7f9d00e6b5a47393887378787c1c9c37784add5ee8a77b8c78abe1fd24856.

---

<a id="pubmed-pmid-30764032-tesamorelin-v1"></a>

## PubMed record PMID 30764032

> PeptideScanner retained PubMed bibliographic metadata for PMID 30764032 at 2026-07-30T20:44:20.588Z. PubMed recorded a metadata revision date of 2019-11-20 and an Entrez history date of 2019-02-16. PeptideScanner associated this retained record with the identity slug tesamorelin. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-30764032-tesamorelin:v1`
- Evidence domain: Literature metadata
- Date in source: 2019-11-20
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-30764032-tesamorelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tesamorelin.json#pubmed-pmid-30764032-tesamorelin-v1
- Content SHA-256: `44b34056a2b9e9a7b187f6b443d2ad5d81b86bd950c9b93f91eccc99ac6eaed8`

### Claims and source pins

#### Headline

PubMed record PMID 30764032 ([`pubmed-observation-pmid-30764032-2019-11-20-257b389361f9`](#source-pubmed-observation-pmid-30764032-2019-11-20-257b389361f9))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 30764032 at 2026-07-30T20:44:20.588Z. PubMed recorded a metadata revision date of 2019-11-20 and an Entrez history date of 2019-02-16. PeptideScanner associated this retained record with the identity slug tesamorelin. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-30764032-2019-11-20-257b389361f9`](#source-pubmed-observation-pmid-30764032-2019-11-20-257b389361f9))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 30764032 at 2026-07-30T20:44:20.588Z. PubMed recorded a metadata revision date of 2019-11-20 and an Entrez history date of 2019-02-16. PeptideScanner associated this retained record with the identity slug tesamorelin. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-30764032-2019-11-20-257b389361f9`](#source-pubmed-observation-pmid-30764032-2019-11-20-257b389361f9))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-30764032-2019-11-20-257b389361f9`](#source-pubmed-observation-pmid-30764032-2019-11-20-257b389361f9))

### Sources

<a id="source-pubmed-observation-pmid-30764032-2019-11-20-257b389361f9"></a>
- **PubMed record PMID 30764032 · retained source version 1:2019-11-20:current:257b389361f90d7a3a96101b8596dbeb1ac99ae3bbbca0a9133b99365ece38ef** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/30764032/) (`pubmed-observation-pmid-30764032-2019-11-20-257b389361f9`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 30764032." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/tesamorelin.json#pubmed-pmid-30764032-tesamorelin-v1 SHA-256: 44b34056a2b9e9a7b187f6b443d2ad5d81b86bd950c9b93f91eccc99ac6eaed8.

---

<a id="pubmed-pmid-31237318-tesamorelin-v1"></a>

## PubMed record PMID 31237318

> PeptideScanner retained PubMed bibliographic metadata for PMID 31237318 at 2026-07-30T20:30:10.504Z. PubMed recorded a metadata revision date of 2020-04-07 and an Entrez history date of 2019-06-26. PeptideScanner associated this retained record with the identity slug tesamorelin. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-31237318-tesamorelin:v1`
- Evidence domain: Literature metadata
- Date in source: 2020-04-07
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-31237318-tesamorelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tesamorelin.json#pubmed-pmid-31237318-tesamorelin-v1
- Content SHA-256: `3fc4ab37db7e644fcd6083234674c6de05777839927b123dddd7ed0efc5ef29c`

### Claims and source pins

#### Headline

PubMed record PMID 31237318 ([`pubmed-observation-pmid-31237318-2020-04-07-3c25c51ff130`](#source-pubmed-observation-pmid-31237318-2020-04-07-3c25c51ff130))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 31237318 at 2026-07-30T20:30:10.504Z. PubMed recorded a metadata revision date of 2020-04-07 and an Entrez history date of 2019-06-26. PeptideScanner associated this retained record with the identity slug tesamorelin. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-31237318-2020-04-07-3c25c51ff130`](#source-pubmed-observation-pmid-31237318-2020-04-07-3c25c51ff130))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 31237318 at 2026-07-30T20:30:10.504Z. PubMed recorded a metadata revision date of 2020-04-07 and an Entrez history date of 2019-06-26. PeptideScanner associated this retained record with the identity slug tesamorelin. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-31237318-2020-04-07-3c25c51ff130`](#source-pubmed-observation-pmid-31237318-2020-04-07-3c25c51ff130))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-31237318-2020-04-07-3c25c51ff130`](#source-pubmed-observation-pmid-31237318-2020-04-07-3c25c51ff130))

### Sources

<a id="source-pubmed-observation-pmid-31237318-2020-04-07-3c25c51ff130"></a>
- **PubMed record PMID 31237318 · retained source version 1:2020-04-07:current:3c25c51ff13093a812d3f8eb41eff334ac5fbb059dbfc11751bfd66b31f8387f** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/31237318/) (`pubmed-observation-pmid-31237318-2020-04-07-3c25c51ff130`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 31237318." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/tesamorelin.json#pubmed-pmid-31237318-tesamorelin-v1 SHA-256: 3fc4ab37db7e644fcd6083234674c6de05777839927b123dddd7ed0efc5ef29c.

---

<a id="pubmed-pmid-34006921-tesamorelin-v1"></a>

## PubMed record PMID 34006921

> PeptideScanner retained PubMed bibliographic metadata for PMID 34006921 at 2026-07-30T16:22:11.959Z. PubMed recorded a metadata revision date of 2026-04-07 and an Entrez history date of 2021-05-19. PeptideScanner associated this retained record with the identity slug tesamorelin. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-34006921-tesamorelin:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-04-07
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-34006921-tesamorelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tesamorelin.json#pubmed-pmid-34006921-tesamorelin-v1
- Content SHA-256: `72eeba5c672bee72cd3998d2595b0b4b3b13f165f68855cfdac180769e5a0c83`

### Claims and source pins

#### Headline

PubMed record PMID 34006921 ([`pubmed-observation-pmid-34006921-2026-04-07-c17856fc3929`](#source-pubmed-observation-pmid-34006921-2026-04-07-c17856fc3929))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 34006921 at 2026-07-30T16:22:11.959Z. PubMed recorded a metadata revision date of 2026-04-07 and an Entrez history date of 2021-05-19. PeptideScanner associated this retained record with the identity slug tesamorelin. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-34006921-2026-04-07-c17856fc3929`](#source-pubmed-observation-pmid-34006921-2026-04-07-c17856fc3929))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 34006921 at 2026-07-30T16:22:11.959Z. PubMed recorded a metadata revision date of 2026-04-07 and an Entrez history date of 2021-05-19. PeptideScanner associated this retained record with the identity slug tesamorelin. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-34006921-2026-04-07-c17856fc3929`](#source-pubmed-observation-pmid-34006921-2026-04-07-c17856fc3929))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-34006921-2026-04-07-c17856fc3929`](#source-pubmed-observation-pmid-34006921-2026-04-07-c17856fc3929))

### Sources

<a id="source-pubmed-observation-pmid-34006921-2026-04-07-c17856fc3929"></a>
- **PubMed record PMID 34006921 · retained source version 1:2026-04-07:current:c17856fc3929b6fb85bf8fb21aa76c5463f13b6aca827754d6a64d7242549565** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/34006921/) (`pubmed-observation-pmid-34006921-2026-04-07-c17856fc3929`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 34006921." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/tesamorelin.json#pubmed-pmid-34006921-tesamorelin-v1 SHA-256: 72eeba5c672bee72cd3998d2595b0b4b3b13f165f68855cfdac180769e5a0c83.

---

<a id="pubmed-pmid-38905488-tesamorelin-v1"></a>

## PubMed record PMID 38905488

> PeptideScanner retained PubMed bibliographic metadata for PMID 38905488 at 2026-07-30T16:22:12.148Z. PubMed recorded a metadata revision date of 2026-04-01 and an Entrez history date of 2024-06-21. PeptideScanner associated this retained record with the identity slug tesamorelin. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-38905488-tesamorelin:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-04-01
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-38905488-tesamorelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tesamorelin.json#pubmed-pmid-38905488-tesamorelin-v1
- Content SHA-256: `1ecddcbbf59de746db3f1f76175ae98be6c172b2225c0900626515e8e1a33133`

### Claims and source pins

#### Headline

PubMed record PMID 38905488 ([`pubmed-observation-pmid-38905488-2026-04-01-c35eb3ca44aa`](#source-pubmed-observation-pmid-38905488-2026-04-01-c35eb3ca44aa))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 38905488 at 2026-07-30T16:22:12.148Z. PubMed recorded a metadata revision date of 2026-04-01 and an Entrez history date of 2024-06-21. PeptideScanner associated this retained record with the identity slug tesamorelin. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-38905488-2026-04-01-c35eb3ca44aa`](#source-pubmed-observation-pmid-38905488-2026-04-01-c35eb3ca44aa))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 38905488 at 2026-07-30T16:22:12.148Z. PubMed recorded a metadata revision date of 2026-04-01 and an Entrez history date of 2024-06-21. PeptideScanner associated this retained record with the identity slug tesamorelin. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-38905488-2026-04-01-c35eb3ca44aa`](#source-pubmed-observation-pmid-38905488-2026-04-01-c35eb3ca44aa))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-38905488-2026-04-01-c35eb3ca44aa`](#source-pubmed-observation-pmid-38905488-2026-04-01-c35eb3ca44aa))

### Sources

<a id="source-pubmed-observation-pmid-38905488-2026-04-01-c35eb3ca44aa"></a>
- **PubMed record PMID 38905488 · retained source version 1:2026-04-01:current:c35eb3ca44aa8832fb8ac63e6f3218595c0b9e91b59b8aa9f2f4e69f8fd68608** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/38905488/) (`pubmed-observation-pmid-38905488-2026-04-01-c35eb3ca44aa`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 38905488." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/tesamorelin.json#pubmed-pmid-38905488-tesamorelin-v1 SHA-256: 1ecddcbbf59de746db3f1f76175ae98be6c172b2225c0900626515e8e1a33133.

---

<a id="pubmed-pmid-41545261-tesamorelin-v1"></a>

## PubMed record PMID 41545261

> PeptideScanner retained PubMed bibliographic metadata for PMID 41545261 at 2026-08-10T10:49:08.747Z. PubMed recorded a metadata revision date of 2026-08-02 and an Entrez history date of 2026-01-16. PeptideScanner associated this retained record with the identity slug tesamorelin. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-41545261-tesamorelin:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-02
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-10
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-41545261-tesamorelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tesamorelin.json#pubmed-pmid-41545261-tesamorelin-v1
- Content SHA-256: `8399531924794c666e643ad3c89aa11d5c73d6e09e051f0b667ac9d9438f312a`

### Claims and source pins

#### Headline

PubMed record PMID 41545261 ([`pubmed-observation-pmid-41545261-2026-08-02-2172c39e7e97`](#source-pubmed-observation-pmid-41545261-2026-08-02-2172c39e7e97))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 41545261 at 2026-08-10T10:49:08.747Z. PubMed recorded a metadata revision date of 2026-08-02 and an Entrez history date of 2026-01-16. PeptideScanner associated this retained record with the identity slug tesamorelin. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-41545261-2026-08-02-2172c39e7e97`](#source-pubmed-observation-pmid-41545261-2026-08-02-2172c39e7e97))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 41545261 at 2026-08-10T10:49:08.747Z. PubMed recorded a metadata revision date of 2026-08-02 and an Entrez history date of 2026-01-16. PeptideScanner associated this retained record with the identity slug tesamorelin. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-41545261-2026-08-02-2172c39e7e97`](#source-pubmed-observation-pmid-41545261-2026-08-02-2172c39e7e97))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-41545261-2026-08-02-2172c39e7e97`](#source-pubmed-observation-pmid-41545261-2026-08-02-2172c39e7e97))

### Sources

<a id="source-pubmed-observation-pmid-41545261-2026-08-02-2172c39e7e97"></a>
- **PubMed record PMID 41545261 · retained source version 1:2026-08-02:current:2172c39e7e97ce046da26d60e5a4fed7b73be5f89478292ec4ec34191afd5615** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/41545261/) (`pubmed-observation-pmid-41545261-2026-08-02-2172c39e7e97`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 41545261." Version 1, published 2026-08-10. https://peptidescanner.com/evidence/v1/peptides/tesamorelin.json#pubmed-pmid-41545261-tesamorelin-v1 SHA-256: 8399531924794c666e643ad3c89aa11d5c73d6e09e051f0b667ac9d9438f312a.

---

<a id="pubmed-pmid-42419889-tesamorelin-v1"></a>

## PubMed record PMID 42419889

> PeptideScanner retained PubMed bibliographic metadata for PMID 42419889 at 2026-08-10T10:49:10.753Z. PubMed recorded a metadata revision date of 2026-07-30 and an Entrez history date of 2026-07-08. PeptideScanner associated this retained record with the identity slug tesamorelin. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-42419889-tesamorelin:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-30
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-10
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42419889-tesamorelin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tesamorelin.json#pubmed-pmid-42419889-tesamorelin-v1
- Content SHA-256: `3627aef5ad2528567e1f58bae76275ba53bbc01fb04a809ea6ec7f0563dad5ea`

### Claims and source pins

#### Headline

PubMed record PMID 42419889 ([`pubmed-observation-pmid-42419889-2026-07-30-adfe648624cd`](#source-pubmed-observation-pmid-42419889-2026-07-30-adfe648624cd))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 42419889 at 2026-08-10T10:49:10.753Z. PubMed recorded a metadata revision date of 2026-07-30 and an Entrez history date of 2026-07-08. PeptideScanner associated this retained record with the identity slug tesamorelin. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42419889-2026-07-30-adfe648624cd`](#source-pubmed-observation-pmid-42419889-2026-07-30-adfe648624cd))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 42419889 at 2026-08-10T10:49:10.753Z. PubMed recorded a metadata revision date of 2026-07-30 and an Entrez history date of 2026-07-08. PeptideScanner associated this retained record with the identity slug tesamorelin. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42419889-2026-07-30-adfe648624cd`](#source-pubmed-observation-pmid-42419889-2026-07-30-adfe648624cd))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42419889-2026-07-30-adfe648624cd`](#source-pubmed-observation-pmid-42419889-2026-07-30-adfe648624cd))

### Sources

<a id="source-pubmed-observation-pmid-42419889-2026-07-30-adfe648624cd"></a>
- **PubMed record PMID 42419889 · retained source version 1:2026-07-30:current:adfe648624cd1882ff79d18a2f5d34334674e0e201a4a7feccce601dea4a6804** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42419889/) (`pubmed-observation-pmid-42419889-2026-07-30-adfe648624cd`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 42419889." Version 1, published 2026-08-10. https://peptidescanner.com/evidence/v1/peptides/tesamorelin.json#pubmed-pmid-42419889-tesamorelin-v1 SHA-256: 3627aef5ad2528567e1f58bae76275ba53bbc01fb04a809ea6ec7f0563dad5ea.

